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PROBLEM 
a) To determine whether ester-like linkages are present in the 
primary, secondary, or tertiary structures of human .fibrinogen 
and .fibrin, and whether such linkages are related to the 
carbohydrate moieties of fibrinogen. 
b) To demonstrate and attempt to characterize the carbohydrate 
and peptide changes occurring during the conversion of human 
fibrinogen to fibrin by the action of human thrombin. 
c) To study same of the effects which S-amino caproic acid, 
heparin, and other agents have on the conversion of human 
fibrinogen to fibrin. To evaluate whether the effects of 
heparin are related to the enzymatic activity of human 
thrombin or to the polymerization of fibrin. 
BACKG~OUND 
I. HISTORICAL 
a) Preparation of Fibrinogen 
The coagulation of blood is one of the vital processes of life 
observed since biblical time. The entire process of transforming 
the free-flowing blood into a stable mechanical structure is initiated 
instantly and is generally regarded as completed within six to eight 
minutes. The major protein substance involved in blood coagulation 
was first isolated by Malpighi (1686) who described a white fibrous 
substance obtained from the red blood clot through washing with 
water. Malpighi also observed that neutral salts would retard or 
completely inhibit the coagulation of blood. Later, Nasse (1836) 
showed that fibrinogen could be salted out of plasma by means of 
sodium sulfate or saturated sodium chloride and upon dilution with 
water would be transformed into fibrin. Denis (1859) also suggested 
the existence of water-insoluble globulins (euglobulins) in plasma. 
Thirteen years (1872) later Alexander Schmidt formed the basis of 
our modern concept of blood coagulation and initiated the principle 
of precipitating fibrinogen and other globulins by dilution with 
slightly acidic water. In 1880 Hammarsten prepared horse fibrinogen 
by repeated precipitation with half-saturated sodium chloride, thereby 
establishing the first major method of plasma protein purification. 
He also reported that fibrinogen does not spontaneously coagulate but 
could be irreversibly heat denatured (+52 to+ ss0c.) and that 
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fibrinogen and fibrin contain 16.66 and 16.91 per cent nitrogen, 
respectively. His nitrogen conversion factor (5.91) for fibrin is 
still acceptable. It would appear that some of Hammarsten's 
fibrinogen preparations were over 90 per cent pure. A series of 
modifications of Hammarsten's fibrinogen purification procedure were 
made by Rettger (1909), Howell (1910), Bardet (1920), Florkin (1930), 
Eagle (1935) and Chargaff and Bendick (1943). All of these modi-
fications were directed at increasing the stability of the 
fibrinogen preparations, by the absorption of prothrombin on cal-
cium triphosphate, calcium fluoride, barium phosphate or sulfate 
and magnesium hydroxide. 
At the end of the 19th century a second major method of fibrinogen 
purification through the use of ammonium sulfate solutions was intro-
duced and studied by Hofmeister (1899) and his many associates. 
McLean (1920), Smith~ !l (1934), Milstone (1941), Astrup and Darling 
(1942), Laki (1942), and Bagdy (1949) further studied the use of 
ammonium sulfate and were able to obtain a 75 to 80 per cent clottable 
fibrinogen. Laki and Bagdy reported the crystallization of swine 
fibrinogen; however, the clottability of Laki's preparation was less 
than 80 per cent, and Bagdy did not cite the clottability of his 
crystalline preparations. Laki continued to modify his original 
procedure, and in 1951 reported that by the proper control of pH, 
ionic strength and temperature, followed.by two ammonium sulfate 
precipitations at 0.21 and 0.25 saturation, a bovine or human 
- 3 -
fibrinogen preparation could be obtained Which was 95 per cent 
clottable. The Laki purification procedure with ammonium sulfate 
yields a fairly stable produce (Ware and Lanchantin, 1954) which can be 
prepared free of plasmin (Katz et !l, 1952). However Seegers (1955) 
claims that the ~ procedure yields a fibrinogen preparation which 
frequently contains blood coagulation components. 
A third major method of fibrinogen purification was described by 
Ware, Guest and Seegers (1947) Who obtained a 97 per cent clottable 
bovine fibrinogen. Their technique was based upon the fact that 
fibrinogen, unlike the other major plasm proteins, has a low solubility 
at low temperatures. By repeatedly freezing and thawing of plasma 
they were able to centrifuge out purified fibrinogen, and discard 
the other soluble plasma proteins. 
The fourth approach at fibrinogen purification was introduced in 
the early 1940's by the Harvard group under the direction of E.J. 
Cohn. They were able to elaborate a now well known cold ethanol-
water variable system for the fractionation of plasma proteins. The 
first fraction (I) of Cohn's method 6 (1946) contains about 80 per 
cent of the human plasma fibrinogen. The further purification of 
fraction I was described by Morrison, Edsanand Miller (1948) and 
their preparation contained between 93 and 98 per cent coagulable 
protein when treated with thrombin. However, upon ultra-
centrifugation, even their purest preparations contained two 
sedimenting components (s20 = 8.55 and 15) and sometimes a more 
-4-
II 
.rapidly sedimenting component. Blomback in a definitive thesis 
dissertation described the preparation of bovine and human fibrinogen 
from Cohn Fraction I. He and his wife (1956) utilized various molar 
concentrations of glycine to raise the dielectric constant of the 
medium and thereby increase the solubility and decrease interactions 
between most of the contaminating proteins in fraction I. Their 
preparations designated as I
4 
were 98 to 100 per cent clottable. 
They were unable to detect prothrombin, thrombin, plasmin, anti-
hemophilic globulin, cold insoluble globulins, or heparin cofactor 
in their preparations and their I4 preparations were found to contain 
about 10 per cent of the plasminogen and pro-activator which was 
originally present in crude fraction I. Their preparations were 
electrophoretically homogeneous and had a sedimentation value of 6.50 
S at pH 8.0, /2 = 0.3, and sedimented as a single peak throughout an 
entire one hour run. Mossessen (1962) utilized lysine and €-amino-
caproic acid to solubilize plasminogen and obtained a "plasminogen-
II 
free" fibrinogen using the Blomback I4 fraction as the starting 
material. Since lysine and €-aminocaproic acid are both potent 
inhibitors of plasmin, the preparation of Mossessen cannot be said to 
be entirely free of plasminogen. Many personal communications have 
II 
confirmed the opinion of this investigator that the Blomback or 
Mossessen methods of preparing human fibrinogen represent the purest 
fibrinogen product which can be currently produced. 
A fifth method for fibrinogen preparation was introduced in 
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England by Kekwick, et al (1946). They were able to obtain 
fibrinogen preparations which were at least 97 per cent clottable 
(Kekwick, et al, 1955). However, the yields are somewhat lower 
than the ethanol fractionation procedure, but the final product 
appears to be about as pure as that described by Morrison et al 
(1948). 
b) Fibrinopeptides 
The purest of fibrinogen when converted into fibrin by the 
action of thrombin was~ always found to leave some proteinaceous 
substances in the supernatant. Hammarsten (1880, 1896) and Schmidt 
(1892) referred to these protein substances as "fibrino-globulins". 
In 1908 Mellanby suggested that fibrinogen is composed of two 
associated proteins and that during coagulation the bond joining 
these groups is broken where upon a quantity of "fibrino-globulins" 
or serum globulins remain in solution. Waldschmidt-Leitz et al 
(1928) suggested that thrombin could be a "trypsin-like" enzyme 
since natural and synthetic trypsin substrates produced inhibition 
of the coagulation of whole blood. In 1937, Eagle showed that 
some snake venoms (Bathrops jararaca) and papain, which both 
contain proteolytic enzymes, could bring about the direct 
conversion of fibrinogen into fibrin. A year later Presnell 
demonstrated that the total nitrogen in fibrin formed by the action 
of thrombin was less than the corresponding amount of heat-coagulated 
fibrinogen. He also demonstrated by formal titration that the 
number of free amimo groups was increased during the coagulation of 
fibrinogen. Van Slyke (1941) was aware of the ninhydrin-reacting 
materials in picric acid filtrates of plasma and serum. Because of 
the variable results obtained with serum filtrates, the plasma was 
recommended for the van Slyke amino acid analysis. In a simple, yet 
now classical experiment, Lorand (1951, 1952) demonstrated that 
during the fibrinogen-fibrin conversion by thrombin, there is a 
sharp rise in non-protein nitrogen which levels off at about 3 per 
cent of the total nitrogen present. From 1952 to 1958 a series of 
several articles appeared separately by Bailey, Bettelheim and 
Bailey (1952), Lorand and Middlebrook (1952, 1953), Bettelheim (1956), 
II II 
Blomback and Yamashina (1958) and Blomback and Vestermark (1958), which 
adequately described the amino acid composition, paper electrophoretic 
behavior, molecular weight, and resin column characteristics of bovine 
fibrinopeptides. During the fibrinogen-fibrin conversion two moles 
each of fibrinopeptides A and B per mole of fibrinogen were found. 
The amino acid sequence of these bovine fibrinopeptides suggested by 
II 
the above mentioned workers have been confirmed by Blomback et al. 
(1959), Gladner et al. (1959) Folk and Gladner (1960) and Sjoquist (1960). 
The fibrinopeptides A (mol. wt. 1,890) was described as containing 19 
amino acid residues. Two residues of serine and no tyrosine were found in 
the hydrolysates of fibrinopeptide A. The fibrinopeptide B (ml. wt. 2,460) 
was described as containing 21 amino acid residues. One tyrosine 
and no serine residues were found in the acid hydrolysates of this 
fibrinopeptide. The tyrosine is present in the fibrinopeptide B as 
tyrosine-0-sulfate ester (Bettelheim, 1954). This form of tyrosine ester 
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is unique in that it has not been demonstrated in any other mammalian 
protein. The proposed structures of the bovine fibrinopeptide are 
given below: 
PEPTIDE A. 
Glu (AspJ-Ser2-Pro2-GlY2)-Ala-Leu-Thr-(Glu-Gly3)val-Arg 
M.w. = 1,890 
PEPTIDE B. 
~04 
N-acetyl-Thr-Glu-Ala-Pro-Asp-Tyr-Asp-Glu-Gly-Glu-Asp2-Arg-
Pro-Lys-Val-Gly-Leu-Gly-Ala-Arg 
M.w. = 2,460 
All of the information thus far presented has applied to the 
bovine fibrinogen-fibrin conversion system. The human system has 
thus far not been thoroughly investigated with regard to the nature 
of the fibrinopeptides. This dissertation represents a modest 
beginning directed at some of the marked differences in the human 
and bovine systems. These differences were so great that repeated 
experiments were necessary to confirm them, and at times modifications 
of present procedures had to be used which lengthened an otherwise 
simple analytical approach. 
II. Evidence of Primary carbohydrate-Protein Structures with Ester-
Linkages. 
The proteins used in the experiments of this dissertation 
have not been previously studied for ester-like linkages. However, 
the following proteins have been studied and a brief summary of the 
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results is presented here. These studies have contributed some of 
the methodology used in this dissertation. Furthermore some analogy 
between diverse proteins might be anticipated in regards to the 
protein-carbohydrate linkages. 
a) Collagen 
Crystallized connective tissue proteins (procollagen and 
collagen) contain hexoses (0.42 to 2.71%) and three types of co-
ordinate bond linkages between carbohydrate and protein have been 
suggested by Grassmann et al (1957). (1) N-glycosidic linkages 
between sugar and amino groups of the protein. {2) 0-glycosidic 
linkages to the hydroxy groups of hydroxyamino acids. {3) Ester-
linkages between the alcoholic hydroxy groups of sugars and the carboxyl 
groups of the protein. Grassmann, Endres, and Steber (1954) demonstrated 
early evidence of such ester-linkages in procollagen by the formation 
of alcohols following treatment with lithium borohydride. The 
lithium borohydride reaction with collagen led Grassmann (1955) to 
the isolation of a gluco-peptide, glucosaminyl-leucyl-diglycyl-
alaninol. A review by Fraenkel-Conrat (1956) discusses the point as to 
whether the C-terminal amino-acids of collagen are esterified or free. 
A series of papers by Gallop, Seifter, Franzblau et al (1959, 
1960, 1962) has presented more evidence that glucose is the alcohol 
donor of the ester bonds in ichthyocol (collagen derived from fish 
swim bladder). 
Their group employed the hydrazine and hydroxamate reactions 
for the determination of esters and concluded that two or three 
ester bonds are linked through the alpha-carboxyl group of aspartic 
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acid and that the beta-carbexyl groups of asparatic acid participate 
in the other three ester bonds. They suggest eight ester bonds per 
molecule of ichythyocol (or, 6 per 1,000 amino acid residues). 
After reviewing the series of papers presented by the Gallop 
group, the writer was impressed by the lack of information regarding 
the nature of the carbohydrates and the amounts which were present 
in the commercial gelatin preparations which they also studied. One 
can only surmise that at least glucose and galactose in the ratio of 
1:1 are present in ichthyocol. (Loeven, 1955; Schneider, 1949). The 
earlier reports from the Gallop group presented evidence of the 
"ester-like" or perhaps imide linkages between units of amino acid 
chains of about 20,000 molecular weight. In view of their latest 
conclusions regarding the glucosidic linkage, one may postulate 
t&at the molecule of an alpha-unit of procollagen consists of three 
low molecular weight "protein backbone" units held together or 
interspaced with ester-linkages to the disaccharide lactose. Bello 
II (1960) and Hormann (1960) suggested that "ester-like" bonds are 
involved in intermolecular and intramolecular cross-linkages. 
de la Burde, Peckham,Vies (1963) indicated that the hydrazine reaction 
employed by Gallop ~ al may be the result of an early reaction due to 
deamidation and later to deguanidination. 
b) Ovine Submaxillary Mucoprotein {OSM) 
A classical series of reports on ovine, submaxillary muco-
protein (OSM) by Gottschalk, ~ al (1959, 1960, 1960a, 1961) indicated 
a convincing demonstration of ester-linkages. The mucoprotein OSM contains 42% 
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hexoses, consisting of equimolecular amounts of N-acetyl neuraminic 
acid and N-acetyl galactosamine, a high percentage of amino di-
carboxylic acids (10.7) and only 0.33% total amide nitrogen. One's 
attention is drawn to the numerous and elegant approaches which these 
investigators used to demonstrate ester bonds in OSM. First, they 
used crystalline enzymes as analytical reagents for the partial 
hydrolysis of proteins or polypeptides and disaccharides. secondly, 
they used the most appropriate conditions under which lithium boro-
hydride will reduce the ester groups to their corresponding alcohols, 
(but will not react with the acid amide groups and with less than 2% 
of the total peptide bonds of proteins). The conclusions of the 
Gottschalk group concerning the mucoprotein fragment from OSM indicate 
that about 80% of the prosthetic groups are involved in a glycosidic-
ester linkage to the free carboxyl groups of aspartyl and glutamyl 
residues, and that about 18% of the total N-acetyl neuraminic acid in 
OSM is bound by an 0-glycosidic linkage to the hydroxyl groups of 
serine and/or threonine residues. Unlike the carbohydrates involved 
in collagen, those found in the prosthetic group of OSM are 
disaccharide units of«-D-N-acetylneuraminyl (2~6) N-acetylgalactosa-
mine. In other words, the protein core of OSM has about 80% of the 
carboxyl groups of aspartic and/or glutamic acids involved as ester 
linkages with the hydroxyl groups of the disaccharide units (probably 
through the N-acetylgalactosamine moieties, since the N-acetyl 
neuraminic acids are the terminal units of OSM). The remaining 18% 
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of the disaccharide units are covalently linked to the OSM protein 
core by stable 0-glycosidic linkages with serine and/or threonine. 
Furthermore, the OSM protein core probably consists of~-helix 
segments "loosely-held" by proline residues, and the disaccharide 
units forming a secondary incomplete helix around the protein core. 
c) Ovalbumin 
There have been to date three glyco-peptides isolated from 
tryptic digests of crystalline ovalbumin (Cunningham, 1957; Jevons, 
1958; and Johansen, 1958). The ovalbumin used in the latter two of 
these experiments was that prepared by Neuberger,(l958) which contained 
1.81 mannose and 0.9% glucosamine. The carbohydrate-amino acid 
structures of these three 8lyco-peptides are remarkably similar in 
that each contain mannose:glucosaudne (N-acetyl glucosamine):aspartic 
acid:leucine in proportions approximately of 4:2:1:1. The other amino 
acids recovered were serine and threonine. Upon further digestion 
of the glyco-peptide with carboxypeptidase, Johansen obtained a 
carbohydrate-containing fragment with only one mole of aspartic acid 
and trace amounts of threonine and serine, and suggested that one 
carboxyl of aspartic acid was linked with carbohydrate and the other 
carboxyl of this amino acid was linked to leucine. He found no 
experimental evidence to support the existence of O~glycosidic 
linkages involving the hydroxyl groups of threonine or serine as 
originally suggested by Werner (1953). A most recent investigation by 
Lee and Montgomery (1962) indicates that ovalbumin contains a single 
unit of oligosaccharide with the end amino acid-carbohydrate sequence 
being glu-lys-tyr-asp-carbohydrate. 
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d) Fetuin 
R.G. Spiro (1960, 1962) isolated a glycoprotein of fetal calf 
serum (fetuin) and subjected it to digestion with various proteolytic 
enzymes (pepsin, chymotrypsin, trypsin, nagarse, and papain). As a 
result of DEAE-cellulose chromatography of the pepsin and nagarse 
digest of fetuin, he was able to obtain seven distinct glycopeptide 
residues which contained all of the sugar in the same molar ratio 
present in the original fetuin. He stated that the most likely 
composition of the polysaccharide units of the glycopeptides would 
be 4 residues of sialic acid, 4 residues of galactose, 6 residues of 
hexosaudnes, and 3 residues of mannose. The amino acids most 
frequently occurring in the vicinity of the three_ carbohydrate-
peptide linkages were aspartic acid, alanine, serine and proline. 
Eylar (1962) suggested that the li~kages between amino acids and carbo-
hydrates were through the reducing groups of N-acetylglucosamine to 
the beta-carboxyl group of aspartic acid. The diagrammatic represen--
tation of the carbohydrates and their linkages is presented here with 
permission of Dr. Spiro (1962J. 
Basic Oligosaccharide chain of fetuin. 
N-acetyl neuraminic acid - galactose - N-acetyl glucosamine 
Entire heteropolysaccharide unit showing the oligosaccharide chains 
attached to inner portion. Molecular wt. of each heteropolysaccharide 
unit = 3500. 
coo coo coo coo coo 
' 
= N-acetyl neuraminic acid 
• • • • • 
X X X X X = Galactose 
0 0 0 0 0 = N-acetyl glycosamine 
f<GNAc,Mann,Mann,Mann)-GNAc GNAc = N-acetylhexosamine 
I 
I 
I 
PROTEIN 
There are three heteropolysaccharide units attached at three points 
along the single chain of fetuin. 
III. Carbohydrates Associated with Human Albumin, Fibrinogen, and 
Fibrin. 
The following human plasma proteins were used during this 
investigation and a more detailed description of their characteristics 
are presented. 
a) Albumin 
crude human albumin (Cohn's Fraction V) contains at least 
0.5% hexoses (presumably as alpha glycoproteins). However, analyses 
of several different lot preparations of Fraction V showed great 
variations in hexose content; one lot contained as much as 2.5%. 
By further ethanol or ammonium sulfate fractionation of human plasma 
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albumin, a crystalline product was obtained by Kendall (1941) and Cohn 
~ al (1947) which was reported as carbohydrate-free (as tested by the 
orcinol reaction). According to Tristram (1953) the audno acid residue 
analysis of crystalline albumin bas been said to account for 92.97~ 
of its nitrogen. The treatment of crystalline human plasma albumin 
with mercuric chloride and resin fractionation has led to the preparation 
of an "albumin dimer" and mercaptalbumin (Allerton, 1961). 
The solubility of human crystalline albumin appears to be 
influenced by the variable amounts of lipid (2.9 to 0.4%) which it 
contains. Crystalline mercaptalbumin preparations (Purdy, 1962) 
were found to contain the least amount of fatty acids (i.e. between 0.5 
and 1.0 mole of fatty acid per mole of albumin). 
b) Fibrinogen and Fibrin 
Part of the studies reported below is devoted to the possible 
existence of ester-type linkages in ~ibrinogen and fibrin. There are 
several excellent reviews concerning the purification, p~ysical chemical 
II 
properties, and amino acid composition of fibrinogen and fibrin (Blomback, 
1958; Scheraga and Laskowski, 1957; and Scberaga, 1961). Some of those 
characteristics of fibrinogen and fibrin which are pertinent to this study are 
presented here. 
The carbohydrate content of the previously mentioned proteins 
(albumin, ovalbumin, fetuin, and OSM) is documented by many 
investigators. The nature of the di- and poly-saccharides and their 
linkages with the protein moiety is currently being investigated. 
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There are on the other hand only two reports concerning the total 
carbohydrate content of human fibrinogen and fibrin. According to 
Consden and Stanier (1952, 1953), human fibrinogen contains 4.6~ 
reducing sugars and 1.11 hexosamine, While fibrin contains 2.7% 
reducing sugars and 0.6% hexosamine. Their fibrin was obtained 
directly from human plasma, and the purity of the fibrinogen used in 
their analysis was not indicated. The only other report, that of St. 
Sz~ra and Bagdy (1953), indicated that there was 1.73 ± 0.01% hexoses. 
The fibrinogen used in these analyses was reported as 95-98~ cl.ttable, 
and was crystallized according to Bagdy's technique, although they 
give insufficient details of the crystallization procedure. They 
" were unable to detect the presence of "sialic acids", yet Bohm 
and laumeister (1955) were able to isolate 0.64 to 0.89% "neuraminic 
acids'! from the fibrin of normal human plasma. The carbohydrates 
obtained by prolonged acid hydrolysis (110°c) were identified as 
galactose, mannose, and glucosamine. The uronic acids were reported 
as not present (Consden and Stander, 1953). More details of the 
analyses of bovine fibrinogen and fibrin, taken from the papers of 
" Bagdy and Blomback, are illustrated in the following table: 
hexoses glucosamine sialic acid 
(% dry wt.) (% dry wt.) (% dry wt.) 
Bovine fibrinogen 1.64 ± 0.02 0.56 ± 0.02 none 
Fibrin 1.33 ± 0.04 0.54 ± 0.01 none 
Bovine Fibrinogen 3.2 + 0.3 1.0 0.8 
Fibrin 2.8 + 0.2 1.0 0.8 
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II II 
Blomback and Blomback (1957) have indicated that the sialic 
acid in fibrinogen is of the ovine type. All of the above analyses 
indicated a 10-201 difference between fibrinogen and fibrin which 
suggests,ithat carbohydrates release occurs during clotting. As 
indicated by Scherage (1957), "thus far, this problem. of the apparent 
liberation of carbohydrate has not been resolved". 
IV. Discussion 2t Problem 
Because human albUDdn lacks carbohydrates in its structure, it 
was chosen as the reference protein for this investigation of the 
carbohydrates and ester linkages of fibrinogen. If "ester-like'~ 
bonds were found in albumdn they would be typical of intramolecular 
ester cross-linkages due to secondary or tertiary structure, rather 
than carbohydrate esters. Humancx1-glycoprotein was chosen as the 
second reference .protein because nester-like" bonds found in this 
protein would suggest carbohydrate esters. There were no reports 
concerning the existence of "ester-like" bonds in either human 
albumin, QCl-glycoprotein, or fibrinogen. 
The second portion of the problem concerning the release of 
fibrinopeptides during the human fibrinogen-fibrin conversion has 
not been fully studied. However, the amounts of peptides and carbo-
hydrates released during the bovine fibrinogen-fibrin conversion were 
clear from the following calculations: When 330 mgm. of fibrinogen 
are converted into fibrin, there are released about 9.9 mgm 
of fibrinopeptide nitrogen, and between 1.1 and 6.3 mgm. of 
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carbohydrates. Normal human plasma contains about 330 mgm. of 
fibrinogen per 100 ml. 
A third problem, namely the unusual effects of heparin 
on the relatively purified coagulation system of thrombin and 
fibrinogen was made evident when it was observed that the effects 
of heparin were on the polymerization of fibrin. The problem was 
further complicated when it was observed that certain thrombin 
preparations when treated with small amounts of heparin would result 
in the increase of enzymatic activity of some thrombin 
preparations but not others. 
EXPERIMENTAL 
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I. Alkaline-hydrazine Treatment of various Plasma Proteins 
a) Human Plasma Albumin 
Three human plasma albumin (Fraction V) preparations, two 
crystalline plasma albumin preparations and a crystalline mercapt-
albumin preparation were obtained through Dr. Pennell of the Protein 
Foundation or Dr. Oncley of Harvard University. All of these 
preparations were analysed to select the most suitable or purest 
preparation for total hexoses (orcinol method of Winzler, 1955). 
Protein nitrogen analyses were made by a Kjeldahl method on an air 
dry weight basis (VanSlyke and Hiller, 1948). The protein content 
. 280 mu 
was checked 1n two cases by u.v. absorption in a Beckman D.u. 
using an extinction coefficient of 5.30 for a 1% solution of human 
albumin and in subsequent calculations the molecular weight was taken 
to be 69,000 (Coh~ et al. 1947). 
Results: 
Preparation % Hexoses* 
Fraction V, Lot # HP-2 0.5 
Fraction V, Lot II 1041 1.2 
Fraction V, Lot # 1077 0.4 
Crystalline albumin Lot fl 1018 Less than 0.1 
Crystalline albumin Lot # HP-2R Less than 0.1 
Mercaptalbumin Less than 0.1 
*Based on mgm. hexoses (mannose/galactose, 1:1) per 100 mgm. protein 
(Kjeldahl nitrogen) 
Lot # 1041 was subjected to electrophoresis on cellulose 
acetate strips using barbital buffer, pH 8.6, /2 0.05. The strips 
were stained with light green s.F. dye in 1% acetic acid. The 
excess stain was eluted with 0.5% acetic acid; the fractions were 
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cut from the cellulose strip, and the protein dye dissolved in 
0.5N NaOH. The eluted protein dye color was redeveloped with 
concentrated acetic acid and read at 625 mu in a Coleman Jr., 
Model 6A. Lot# 1041 was found to contain 4.051« 1-glycoprotein. 
Similar findings for crude Fraction V were previously reported by 
Cohn E.J., tt al :(1947). 
Lot# 1018 was found to be 76.741 protein by triplicate 
Kjeldahl and u.v.280 mu analyses, contained no detectable hexoses, 
and was electrophoretically homogeneous. 150 mgm. of this human 
albumin preparation was dissolved in 10 ml. of 1 Molar hydrazine 
at pH 9.0 and incubated in a 37°C water bath for 90 minutes. The 
unreacted hydrazine was separated and removed from the albumin by 
passing the mixture through a 55 x 220 mm. column (Scientific Glass 
# J-1661) of Sephadex G-50 (Lot ITo 9860M) in the manner described 
by Porath and Flodin (1959). The column was eluted at room temper-
ature (ca. 24°C.) with l%(w/v) monochl~~acetic acid (MCA) solution, 
pH 2.0, at the rate of 2.5 ml. per minute. The effective- separation 
of the free hydrazine and albumin on this column shown in Figure I. 
The samples containing the most protein (as determined by 
Kjeldahl nitrogen analysis) were examined for free and heat-labile 
(aooc.) hjdrazine in the manner described by Gallop, ~!! (1960). 
An equal concentration (3.84 mgm./ml.) of untreated crystalline albumin 
dissolved in 11 MCA was used as the appropriate blank solution. 
The results of two separate experiments (Lot I 1018 & HP-2R) showed 
tt L' ~ 
~ ~ ~ 1.0 
~ 
~ 
~ 
~ a 
~ 
~ 
0 
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CHROMATOGRAPHIC SEPARATION OF 
. ALBUMIN OR FIBRINOGEN ANO HYORAZINE 
ON A SEPHAOEX G-SO COLUMN 
t---~L.BVNIN 
I \ 
I \ 
I r/8RINOG£N I 
I \ 
I \ 
I ~ I ~ ' \ \ HYORAZIN£ I \ I ~ t 
\ 
\ 
\ 
' ' 
'o.. 
' \~ 
... 
100 150 200 250 .300 
ml OF £/.l/AT£ 
. t 
Figure 1. - The separation of h~n albumin or fibrinogen from unreacted 
0 hydrazine on a Sephadex G-50 column (55 x 200 mm.) at 24 c. 
with 1% (w/v) monochloroacetic acid at the elution rate of 
280mu 2.5 ml./min. The protein UV absorbances were made 
1 em 
with a Beckman DB. The 460 mu absorbances of the Ehrlich's 
reaction with hydrazine were made with a Coleman 6A. 
2.0 
.350 
-21-
identical column separation, and the mole ratio"' of the heat-labile 
hydrazine to albuudn was found to be 0.20 and 0.28, respectively. 
b) Crystalline Bovine Albumin 
Two preparatt~ of crystalline bovine albumin (Armour's 
Lots #V 68802 and W 69312) and one bovine mercaptalbumin preparation 
were used in these experiments. The U.V. extinction coefficient 
(El1t ) at 280 mu for bovine albumin was taken as 6.60 and the em 
nitrogen conversion factor of 6.23 was used (Brand, 1946). The 
molecular weight used was taken as 65,000 (Creeth, 1952). 
Samples of 150 mgm. each of these protein preparations 
were treated with buffered hydrazine in the manner previously 
described for human plasma albumin. The S~phadex G-50 elution 
characteristics were similar to those for the human plasma albumin 
preparation, and the mole ratio·:: of heat-labile hydrazine to albumin 
was found to be 0.68 (Lot #V 68802) 0.65 (Lot I 69312) and 0.50 
(mercaptalbumin). 
c) Human«1-glycoprotein 
This human plasma glycoprotein was chosen for its purity 
and the 17.2% carbohydrate content. The starting material Cohn 
fraction VI was further purified in the maaner described by Schmid 
(1953). The analysis table given by Schmid was used in the calcu-
l't lations, i.e. 10.7t nitrogen and Elcm at 278 mu equal 8.93. The 
molecular weight was taken as equal 4:o 44,100 (Weimer, ~ al, 1950) 
When 137.25 mgm. of this protein was examined for heat-
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labile hydrazine as previously described; a mole ration of heat-
labile hydrazine tocx1-glycoprotein was found to be 0.32. 
d) Bovine Fibrinogen ~ Fibrin 
The nitrogen conversion factors of 6.02 and 5.91 for 
" fibrinogen and fibrin, respectively were used (Blomback, 1957). 
The extinction coefficient (E~!m> at 280 mu for bovine fibrin and fib-
rinogen were taken as 15.91 (Ferry and Morrison, 1947). This value 
was found to be correct for both fibrin and fibrinq1en in 1% MCA 
solutions. However, the extinction coefficients (El% ) at 280 mu 
lcm 
for bovine fibrin and fibrinogen in alkaline urea were taken as 16.84 
ft II 
and 16.51, respectively (Blomback and Blomback, 1956). The iiscrepancy 
of the extinction values is due to the variance of tYrosine absorption 
in the acid and alkaline pH ranges, which have been demonstrated and 
studied by both Tanford £! al (1955) and Wetlaufer (1962). Fauth 
and Ward (1962) in a preliminary report stated that the Ef~ value 
of 282 mu for fibrinogen in 1! NaOR was 17.3. The molecular weight 
was taken as 340,000 for fibrinogen (Fritzgerald, 1957). The total 
bexoses were determined by the orcinol method, as previously cited. 
The coagulation of fibrinogen and the syneresis of the fibrin clot 
was conducted according to the method of ~rison (1947); although a 
higher concentration of bovine thrombin (20 NIH units/ml.) was used 
(Saifer and Newhouse, 1954). All stock bovine thrombin preparations 
were from Upjohn Company and stored at -20°C. in the dry powder form, 
being dissolved in distilled water just prior to their use. 
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The clottability of two preparations of bovine fibrinogen 
(Armou~s Lots #W5880 and W6321) were 42.0 and 45.11 respectively. 
The average per cent total hexoses (3"analyses) in this fibrinogen 
and fibrin was 3.0 and 2.6, respectively. 
When 100 mgm. of bovine fibrinogen (Lot #W6321) was 
treated for 30 udnutes in 1M hydrazine at pH 7.8 and analyzed after 
72-hour continuous dialysis, the ratio of heat-labile hydrazine to 
protein was found to be 1.72. 
A pilot preparation of 5 grams of Armour's bovine 
fibrinogen was agbjected to purification according to the method of 
II 
Blomback (1958). A 35-401 yield of 95.5% clottable bovine fibrinogen 
was obtained. The expense of the starting material, the low yields, 
and the gross impurities of the bovine thrombin, warran~ed the 
further studies to be conducted on human fibrinegen. 
II. Human Fibrinogen ~ Fibrin 
The nitrogen conversion factors, U.V. extinction coefficients, 
clottability and molecular weight used were the same as those cited 
for bovine fibrinogen and fibrin. The purified human thrombin 
preparation (270 NIH untis/ml.) was obtained by a Cellex-P 
column method and was kindly prepared and supplied by Drs. Fenickel 
and Inman of the Ortho Research Foundation. The human thrombin 
solution was said to be free of plasminogen and plasmin. This 
preparation of thrombin was examined for tyrosine content by the 
Lowry, ~ al (1951) phenol method* and was found to contain 4,320 NIH 
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units/mgm. tyrosine which agreed with the value of 4,100 NIH 
units/mgm. tyrosine found by Dr. Inman!s (1962) laboratory. Seegers, 
~!l (1956) has suggested that pure bovine thrombin may have an 
activity of at least 1,400 units/mgm. dry protein and has obtained 
preparations of 30,000 to 47,000 units/mgm. tyrosine (bovine thrombin 
contains 3.2% tyrosine). Human thrombin has not been consistently 
obtained with the activities given for the bovine preparations. 
During the course of this study two preparations were received in a 
frozen state and were then thawed, diluted with phosphate buffer, 
pH 6.4 r/2 = 0.1. One milliliter aliquots of these diluted samples 
containing from 0.27 to 54.0 NIH units/ml. were kept at -20°C. until 
they were used. 
•> Preparation of Purified Human Fibrinogen ~ Total 
Carbohydrate Contents of Fibrinogen ~ Fibrin. 
The human fibrinogen used in these experiments was prepared 
from crude Cohn fraction I; method 6. The fraction I lots I 507,508, 
and 509 were obtained through the courtesy of the Red Cross 
Fractionation Laboratory. The out-dated whole ACD collected blood 
used to prepare the crude fraction I was said to be processed 
between 30-60 days after the bleeding date. The average day age of 
the citrated whole blood was 45 days. One Lot I 508 was especially 
selected and prepared from 30-day old ACD blood. It was observed 
that the harvested crude fraction I contained variable amounts of 
hemoglobin. The hemoglobin appeared as variegated and striated 
bands in the upper third of the centrifuged precipitate of fraction I. 
The lower portion appeared essentially free of hemoglobin and lots 
# 508 and 509 were prepared from the lower portions. The hemoglobin 
concentrations were not done, but a personal experience with solutions 
of oxyhemoglobin at various concentrations enables one to visually 
estimate the contamination to be about 500 mgm%. 
The purified human fibrinogen (Fraction I 4) was prepared from 
II 
the crude Cohn fraction I according to the method of Blomback and 
II 
Blomback (1956). No attempts were made to obtain lyophilized 
preparations because previous reports indicated a loss of 1 to 5% 
clottability occurred during the freeze-drying procedure (Morrison 
et al, 1948). The stock fibrinogen fraction I4 remained 97-100% 
0 
clottable after two months storage at -20 c. The fibrinogen prep-
arations were removed from the deep freeze for brief periods necessary 
for sample weighing. It was noted that clear ice-like crystals could 
be separated from the frozen fibrinogen fraction I4 during each 
weighing period. The original fraction I4 was found to contain 
25% protein. By the removal or avoidance of the ice-like crystals, 
the fraction I 4 could be made to contain 40% protein. The reader is 
referred to page three of this dissertation describing the freeze-
thawing method of fibrinogen purification. 
The clottability and total hexoses were determined at the 
various precipitating stages during the fibrinogen purification and 
are presented in Table I. At Step 12 where the lowest yield is 
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TABLE I 
The total hexoses and clottability of various fibrinogen fractions 
in per ~ of total protein.* 
t Hexoses t Clottability 
Cohn Fraction I (Fibrinogen) 2.7- 2.0 41 - 53 
Fibrin 2.0 - 1.7 
II 
Blomback Fraction E2 (Fibrinogen) 1.9 Fibrin 1.5 83 - 86 
" Blomback Fraction I2 (Fibrinogen) 1.6 
Fibrin 1.3 
94 - 97 
II 
Blomback Fraction I4 (Fibrinogen) 1.6 
Fibrin 1.3 
97 - 100 
* The carbohydrate components. of fibrinogen and fibrin 
% Hexoses** 1. Hexosamines 1. Sialic Acids** 
II 
Blomback Fraction I4 (Fibrinogen) Fibrin 
1.6 + 0.1 
1.3 + 0.1 
0.6 
0.6 
*The number of analyses, methods, and reference standarcls:are siven 
in the text. 
** The + indicates the range in 1. hexoses and sialic acids of all 
samples analyzed. 
1.0 + 0.1 
0.9 + 0.1 
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obtained (ca. 65%): the cold and insoluble globulin complexes were 
separated from the fibrinogen. These cold-insoluble globulins were 
found to contain 1.6% total hexoses, suggesting that they are 
probably denatured fibrinogen. 
The average total hexoses (34 analyses), hexosamines 
(5 analyses), and sialic acids (27 analyses) values are also given 
for fraction 14• The reference standards were galactose (glucose-
free):mannose (1:1) for total hexoses by a modification of the 
orcinol-HzS04 method described by Winzler (1955) and Vasseur (1948), 
and glucosamine hudrochloride ib~ a modification of the 
p~dimethylaminobenzaldehyde method of Elson and Morg•n (1933) as 
described by the Retina Foundation (1959), and N-acetyl neuraminic 
acid ,•b.y the sialic acid method of Werner and Odin (1952). The 
N-acetyl neuraminic acid was kindly supplied by Dr. Fable Hansen 
(Retina Foundation), and was said to have an extinction value of 
57,000 when tested by the thiobarbituric acid method of Warren (1959). 
All other reference standards were found to be chromatographically 
pure when examined by the method of Dimler, et al (1952). 
b) fhromatographic Identification 21 the Sugars Present ~ 
Fibrinogen 
For the detection of sugars other than sialic acids, 
100-150 mgm. of either fibrinogen or fibrin were hydrolyzed in 5 ml. 
of 1.00 ~H2so4 for 18 hours at 105oc. in nitrogen flushed, 
evacuated, then sealed vials. The hydrolysates were titrated to 
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the pH 7.4 + 0.1 with a saturated solution of barium hydroxide, 
and the excess barium precipitated by bubbling co2 into the suspen-
si-on until a pH of about 5 was reached. The precipitate and most 
of the brown color were separated by dialysis against distilled water 
(4 volumes x 3) at 5°C. in Visking 23/32 dialysis tubing. A 
sealed, B-B shot-weighted glass tube was inserted into the dialysis 
tubing and used to increase the dialysis surface. A magnetic bar 
was previously placed in the bottom of the dialysis bag, and a 
continuous rotary mixing of the dialysate was achieved. The first 
dialysis was over-night, and each subsequent dialysis was for 3 to 4 
hour periods. The combined dialysates, which were clear and nearly 
colorless were concentrated to dryness by freeze drying. The residue 
was dissolved in 0.5 ml. of distilled water and the flask twice 
wahed with 0.5 ml. of distilled water aliquots. The dissolved 
material, and washings were applied to a column (0.75 x 20 em.) of 
Dowex 50-X2, 200-400 mesh (hydrogen form). The sugars except 
hexosamine were eluted from the column with four column volumes of 
distilled water. The eluates were concentrated to a dry residue as 
above and dissolved in 100 lambda of distilled water. Aliquots of 
1 to 5 lambda were used for unidimensional multiple paper chromatography 
according to a modification of the method of Dimler, et al (1952). 
Thin layer chromatography (350 u thickness) was equally effective with 
the following mediums: cellulose phosphate, carboxymethyl cellulose, 
~diethylaminoethyl cellulose, Kieselguhr G, and Silica Gel. All of 
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the8elere used 10% CaS04 as a binder, except in the case of 
carboxymethyl cellulose where a 151 Caso4 binder was found to 
give the most uniform plates. The chromatographic solvent developer 
found most useful in both chromatographic methods was n-butanol: 
pyridine:water (6:4:3 by volume). One' redevelopment with the same 
~lvent was found to give adequate resolution of galactose and 
mannose in all cases. The single development time was 30-40 
minutes for the thin layer and slightly over one hour for the filter 
paper techniquei The plates or the paper were sprayed with either 
p-anisidine-phthalate (Reagent I) or 3,5-dinitrosalicylate 
(Reagent II) as described by Jeanes, !! al (1951). The presence 
of both maanose and galactose in fibrinogen and fibrin were 
confirmed (Plate #1). The same amount of galactose and mannose 
appear in both fibrinogen and fibrin. A more detailed study of 
the rates of galactose and mannose released during graded acid 
hydrolysis '18 being conducted. 
To test for sialic acids, 100-150 mgm. of fibrinogen were 
heated in a glass marble-covered tube with 10 ml. of 0.01 
! H2S04 for one hour at 90°C. as recommended by Svennerho1m (1956). 
Three of these hydrolysate& were combined and treated in the 
manner described for the isolation of hexoses. The paper 
partition chromatography of the sialic acids was conducted in the 
manner described by Svennerholm. The sialic acid reagents which 
were found the most effective were (1) resorcinol and (2) Ehrlich's 
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Plate 1 - The undimensional multiple run (3) chromatogrphic 
separation of mannose, galactose, and glucosamine on Whatman 
#1 (5 x 10 em.) paper with n-butanol:pyridine:water (6:4:3) 
developer. Chromatogram A. represents 10 ugms. each of 
mannose, galactose and glucosamine and the mixture of 
the three standards. Chromatogram B represents a 
mixture of 5 ~ each of mannose and galactose compared 
with the acid digest of fibrin treated as described. 
Chromatogram C represents a mixture of 5 mgms each of 
galactose and mannose compared with the acid digest of 
fibrinogen. 
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reagents (Gottschalk, 1960). A comparison of human ~1-glyco­
protein similarly treated was made and the results are shown in 
Plate 12. The most suitable reference standards would have been 
the N-acetyl and NO-diacetyl neuraminic acids derived from human 
submaxillary glands. The preparation of neuraminic acids from 
human submaxillary glands has not as yet been described, however, 
the method of Blix (1936) described for the ovine (sheep, 
N-acetyl neuraminic acid) types of sialic acids would be most 
appropriate to attempt suCh an isolation. 
c) Some kinetic considerations regarding ~ preparation of 
fibrinogen-hydrazide ~~physico-chemical behavior. 
Samples of 150-200 mgm. of human fibrinogen were treated 
in the same manner as described for human albumin. The samples 
were individually treated with 1 M bydrazine, pH 9.0 for various 
periods of time (15 to 240 minutes). The elution of the human 
fibrinogen-hydrazide from the previously described Sephadex column 
is shown in Figure 1. The mole ratios of beat-labile bydrazine 
to protein were from 0.54 to 3.44, depending on the time of 
treatment. The near maximum amount of bydrazine bound to 
fibrinogen (3.0 ratio) was found to occur in somewhat less than 
90 minutes and did not substantially increase upon prolonged 
incubations (4 hours). The results are illustrated in Figure #2. 
The following experiments were done in order to 
determine the optimal pH conditions for the reaction between 
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Plate 2. - The chromatographic comparison of the sialic acids derived 
from human <X1-glycoprotein and human fibrinogen was 
developed_with n-butanol:n-propanol:O.l! hyd~ochloric 
acid (1:2:1) and identified with resorcinol reagent. The 
RF values for the derived sialic acids were 0.51 and 0.53 
for ~1-glycoprotein and fibrinogen, respectively. 
KINETICS OF TH£ REACTION OF 
FIBRINOGEN !1'/ITH llr1 HY&RAZINE 
/50 
TIMEt OF INCl./BAT/ON IN ld/NI./TES 
Figure 2. - The reaction of 1 Molar buffered (pH 9.0) 
0 
hydrazine and human fibrinogen at 37°c. and the 
moles of "heat-labile" hydrazine formed per mole 
of fibrinogen during the reaction were determined 
as described in the text. 
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human fibrinogen and hydrazine: Human fibrinogen samples of 
150-200 mgm. size were then treated with 1 ~ hydrazine at various 
hydrogen ion concentrations (pH 6.0 to 10.0) for 90 minutes. The 
0 pH measurements were made at 23 c. with a Beckman Model G pH 
meter using an E-2 glass electrode recommended for alkaline 
solutions. The Figure 13 indicates the pH dependence of the 
hydrazine reaction with human fibrinogen, and likewise suggests 
that for the conditions used in this study, that the maximum 
reactivity for hydrazine with fibrinogen is attained at pH's above 
9 (hydrazine PKa = 8.5@ 24°C). 
The effects of varying molar concentrations of hydrazine 
and reaction times at different pH values, and at different 
temperatures were not investigated. 
A number of control experiments were made in order to 
establish that "heat-labile" hydrazine (fibrinogen-hydrazide) 
found in treated fibrinogen was not present in untreated or 
experimentally modified fibrinogens. First, a 163 mgm. sample of 
fibrinogen was brought to - pH 9.0 with 0.1 ~sodium hydroxide 
in a final volume of 10 ml., and carried through the prescribed 
procedure for labile hydrazine detection. Secon~a 144 mgm. 
sample of fibrinogen was treated with 1 ~hydroxylamine, pH 9.0, 
and similarly examined. Third, a sample (0.89 mgm.) of un-
treated fibrinogen dissolved in 2 ml. of 1% MCA was heated with 
the Ehrlich's reagent as described. 
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REACTI0/'1 OF FI8RINOG£1V ltY/T/1 
I 14 HYORAZIN£ AT VAI?/01/S 
HYDROGEN-ION CONCENTRATIONS 
6.0 7.0 8.0 9.0 
pH OF THE F/9RINOGEN-11YORAZIN£ lvfiXTl/R£ 
. t 
Figure 3. - The pH dependence of the reaction between human 
fibrinogen and hydrazine. The mixtures were each 
incubated at 37°c. for 90 minutes and the moles of 
"heat-labile" hydrazine formed per mole of fibrinogen 
werP '.:!etermined as cl~scribed in the te:~t. 
tao 
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In none of these control studies was an absorption 
maximum at 460 mu revealed upon heating with Ehrlich's reagent. 
The maximum absorption wavelength for free hydrazine reacted with 
Ehrlich's reagent is 460 mu. The failure of the controlled 
experiments to reveal an increase of absorbance after heat treat-
ment was taken to mean that no heat-labile substances interfering 
with the hydrazine treatment were present in the controls. The 
recordings of absorbance& at all wavelengths between 700 and 
400 mu were made with a Beckman DB in 1 em. cells. The recordings 
were made for the hydrazine-treated fibrinogen and the fibrinogen 
controls, which were both treated with Ehrlich's reagent (unheated 
and heated). Chart #1 represents a comparison of the 
hydroxylamine-treated sample (line 1) with the hydrazine-treated 
sample (line 2). Both samples contained the same amounts of 
protein (1.48 mgm.) by Kjeldahl nitrogen analyses, and both were 
heated with Ehrlich's reagent as described. The dual beam 
spectrophotometer was set at zero absorbance with the unheated 
Ehrlich's reagent-protein samples as the reference blanks. 
The Chart #2 is a recording of the hydroxylamine-
treated sample (line 1 - Chart #1) being used as the reference 
blank and recording the hydrazine-treated sample as the unknown. 
This comparison indicates the "heat-labile" hydrazine as line 1. 
The line 2 of the Chart #2 represents a comparison of both samples 
treated with Ehrlich's reagent but unheated. The fact that a 
COA1PARATIV£ SP£C TRAL ABSORPTION CURVES 
OF HYOROXYLAMIN£-TREAT£0 (LINE I) ANO 
HYORAZIN£-TREAT£0 (LINE 2J FIBRINOGENS 
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CL.:n: 1- Equal amounts (1.47 mgn:.s.) of hydrad.nc-trcL:tcd and hydroxylami.nc-::n~ated 
(control) human fibrinogens Here trcntcd uHh Eh:~.·Uch' s reagent D~; described 
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very small amount (less than 0.001 uM) of free hydrazine (line 2 -
Chart #2) appears to be present is probably due to the heating of 
the cuvette contents occurring during the recording period. 
Further evidence regarding the existence of fibrinogen-
hydrazine was obtained when equal amounts (17 mgm. each) of the 
alkaline-treated fibrinogen and the fibrinogen-hydrazide were 
reacted with an alkaline-copper tartrate solution and examined 
for copper reduction by the neocuproine method described by 
Brown ( 1960) . - The fibrinogen-hydrazide was able to reduce 
about twice as much copper as the control fibrinogen sample. The 
neocuproine measurements of alkaline copper reduction due to 
hydrazine are sensitive in the ranges of 0.1 to 1.0 UMoles of 
hydrazine in a total volume of 10 milliliters. 
The average total hexose content of three hydrazine-
treated samples was 1.5%. 
It appears that under the conditions described in these 
experiments that 3 moles of hydrazine have reacted with 1 mole of 
fibrinogen to form a "fibrinogen hydrazide". The absorption 
maxima at 630 and 580 mu wavelengths for fibrinogen and other 
proteins heated with Ehrlich's reagent will be presented in 
Part c of this section. 
Some physico-chemical studies were made on the 
fibrinogen hydrazide preparation which was eluted from the column 
with 0.15 M acetate buffer, pH 5.5 instead of 1% MCA. The 
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fibrinogen.hydrazide eluted from the column was not clottable. 
In a control experiment .. :tb.t fibrinogen brought to a pH 9.0 with 
dilute sodium hydroxide, incubated for 90 Ddnutes at 37oc., 
and then eluted from the column with the acetate buffer was 
found to be 84t clottable. It was concluded that the loss of 
clottability on treatment with buffered hydrazine was not due to 
the denaturing effects of the prolonged alkali treatments which 
were used in these experiments. 
The electrophoresis of the fibrino-hydrazide and the untreated 
fibrinogen was performed with the power supply and paper electro-
phoresis cell described by the author (1953). The electrophoresis 
was at 150 volts for 5 hours, at +5°C. using Whatman 3MM paper with 
barbital buffer, pH 8.65, and ionic strength 0.05. Paper electro-
phoresis of these fibrinogen preparations was also performed with 
acetate buffer, pH 5.5, ionic strength 0.05, at 150 volts for 7 
hours at +5°C. The proteins were stained with light green SF or 
ninhydrin spray. At the pH 8.65, the hydrazine-treated fibrinogen 
bad a slightly slower mo~ility toward the anode than did the 
untreated fibrinogen. At the pH 5.5, neither of the fibrinogen 
preparations demonstrated a ~.-:mobility, since this was the !so-
electric value (5.5) for fibrinogen (Mihalyi, 1950). 
The sedimentation characteristics of the hydrazine-
treated fibrinogen and the fibrinogen (fraction I4) 
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preparations were observed and compared using a double sector 
cell in the Spinco Model E analytical ultracentrifuge.* The 
treated fibrinogen was prepared as previously described, but 
eluted from a 0.3 M MaCl equilibrated Sephadex G-50 column with 
0.3 M NaCl solution. The eluates containing the treated 
fibrinogen were concentrated by dialysis over-night at +5°c. 
against a polyethylene glycol compound (Carbowax 20-M}. The 
fibrinogen (fraction I4} and the treated fibrinogen were both made 
to a 1% solution with 0.3 M NaCl as the dilutent. Both 
0 preparations were sedimented in the ultracentrifuge at 20 c. for 
1 hour and 20 minutes after the full rotor speed of 52,640 
rev./min. was obtained, and photographs taken at the Bar angle 
55° (Plate #3). The untreated fibrinogen sedimented as a 
homogenous peak throughout the run. The treated fibrinogen appears 
to sediment at the same rate, but exhibits a peculiar and un-
explained aggregation of molecules. 
A preparation of human fibrin was not readily soluble in 
1 ~ hydrazine, pH 9.0, therefore, approximately 150 mgm. of 
fibrin was dissolved in 5 ml. of 2 ~ NaBr and then 5 ml. of 
2 ~ hydrazine, pH 9.0, was added. The incubation and removal 
of the free hydrazine was performed as in the case of fibrinogen. 
* The ultracentrifuge runs were done through the courtesy of or. 
F. Rothstein, Retina Foundation, Boston, Mass. 
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Plate 3. - The sedimenting characteristics of hydrazine-treated 
fibrinogen (upper) and untreated fibrinogen (lower). 
A standard double sector cell was employed; rotor 
speed: 52.640 rev./min.; Bar angle 55°; time of 
picture 80 minutes. 
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The mole ration of heat-labile hydrazine to fibrin was found to be 
2195. This ratio,, indicates a reduction of 0.25 in the mole ratio 
which was found for fibrinogen; however, the kinetic studies and 
controls for the fibrin experiments were not completed at the 
time of this writing. 
d) ~ possible interference of tryptophan and the 
spectrometric characteristics 2t various proteins 
treated with Ehrlich's reagent. 
The proteins used in this investigation contain variable 
amounts of tryptophan, and the Ehrlich's reagent has been used to 
determdne this amino acid in several proteins. Therefore some 
studies were conducted to determine the extent of interference 
in the sialic acid determination caused by the presence of 
tryptophan residues in fibrinogen. 
There are a variety of p-dimethylaminobenzaldehyde: 
ethanol:ijydroehloric acid mixtures described by Dalgleish (1955) 
which are all referred to as "Ehrlich's Reagent" (ER). The 
Ehrlich's condensation-reaction is also variable with respect to 
temperature, time and other conditions. The Ehrlich's reaction 
has been used to detect indoles, pyrroles, proteins, amino acids, 
sialic acids, sugar and hexosamine& condensed with acetyl-acetone. 
The reaction of ER with tryptophan is said to produce a red to 
green coloration, and the chromogen absorbs &:wavelengths between 
600 and 520 mu. The condensation-reaction of Ehrlich's 
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reagent with tryptophan is said to be similar to that given for 
indoles, ()}+ 
~ 0:-t-):~-0 ~ ex:~ f. -0) 
~ i'"'tt(i) 0 
AI(CH- \ 
Yt. ~(Cii3)z .. 
A composite of the impressions given by Fiegl (1956), Mauzerall 
and Granick (1956). 
The Ehrlich's reagent and its use in these experiments was 
described in Section Ilia. When hydrazine sulfate, !-tryptophan 
and the heat-labile hydrazine derived from fibrinogen-hydrazide 
were each subjected to the Ehrlich's reaction, there were observed 
three very siDdlar spectral responses (Chart #3). All of these 
compounds indicated a maximal absorption at the wavelengths of 
460 mu. However, the reaction of hydrazine (0.025 uM) with ER 
was found to be about a thousandfold more sensitive than that 
with ~tryptophan (20.0 uM). Furthermore, the reaction with hydrazine 
was complete at room temperature (23°C.) in less than 5 minutes and 
did not increase the color density upon further beating (80°C). The 
addition of 2 mgm. (air-dry weight) each of human albumin or 
commercial gelatin to 10 uM of !-tryptophan did not show an 
increase in absorbance at 460 mu with ER which was greater than 
SPECTRAL 0/FFERE/,lC£ O£TV'/££/v 
I-TRYPTOPHAN ANO HYORAZINE 
OR //H£AT-LABIL£// HYORAZIN£ 
___ /.0 
as 
.... HYORAZIA/£ ~ ~ / 0..3 ~ 
/I~ '.\'11 -~ 0./ , 
500 46'0 420 
Y'/AV£L£NGTI-IS mu 
Ch:;rt 3. - Hydrazine sulfate (0. 025 ui.f), 1- tryptophan (20 uM), and human fibrinogen-
hydrazide (1. 76 mgm.) Here each treated "tolith Ehrlich's reagent in the manner 
described under Section III~. The protein nitrogen equivalent of: \"1trcatcd 
fibrinogen tvas used as the reference blank for the fibrinogen- hych:a:;h:c 
( 11heat-labile 11 hydrazine). In the other tuo cases a solution of 1% 
monochloroacetic ncid trcat:r:d \d.th Ehrlich's reagent \'1<1G UE'ed as the 1:cfu:encc. 
blank. The spcctn.l cl:· ·,·tr; HCl'C obtained on a Becb:nn DB rccordir;g 
instrument using 1 c1:. cuvcttec. 
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could be accounted for by the proteins and !-tryptophan, separately 
tested. 
It was concluded that the presence of proteins in the 
Ehrlich's reaction could not account for the increased 460 mu 
absorbance which was observed when the fibrinogen-hydrazide 
preparations·~re heated to caase the liberation of free hydrazine. 
The possible disturbing influence of !-tryptophan upon 
the method used for the determination of hydrazine led to an 
investigation of other compounds which were: 1-tJJosine (40 uM), 
1-proline (40 uM), glycine (50 uM), and 10 uM each of di-,tri-, 
and tetraglycine, D-mannose, D-galactose, D-glucose, D-glucosaudne, 
N-acetyl-D-glucosamine, and N-acetyl neuraminic acid (sialic acid). 
None of these compounds when heated with the Ehrlich's reagent 
would demonstrate any marked spectral characteristics at 460 mu. 
All of the amino acids (except proline), the peptides, and the 
glucosamines revealed a sharp spike-like absorption at 420 mu. 
This spectral behavior was regarded as the condensation products 
of ER and the various primary amines. The N-acetyl neuraminic acid 
demonstrated a peak absorption of 565 mu, which was consistent with 
that demonstrated by Werner and Odin: (1952) for the various glyco-
protein& containing sialic acids. 
The unique spectral curve-changes at 630 and 580 mu 
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for the plasma proteins treated with ER prompted the exploration 
of other proteins. In addition to the plasma proteins used in 
the hydrazine binding experiments, the following proteins were 
reacted with ER: twice crystallized pepsin (Worthington Bio. 
Corp. lot 1642), chymotrypsin (Ref. #311-A89), beef zinc-insulin 
(E. Lilly Co. lot #693502), twice crystallized trypsin salt-free 
(Worthington Bio. Corp. lot #823-24), twice crystallized lysozyme 
derived from egg white (Mann Res. Lab. lot #G-2056), and 
crystallized ovalbumin (Nat. Bio. Lab. lot #G9855). The protein 
nitrogen conversion factors and (molecular weights) were taken as: 
chymotrypsin 6.17 (25,000); trypsin 6.25 (23,800); lysozyme 5.38 
(15,000) and insulin at pH 2.0 (6,000). No corrections were 
made for zinc content since it has been found to vary considerably 
in the commercial preparations. The air-dry weight of insulin 
was taken as the protein content in these calculations. The 
protein concentrations of the other samples were determined by 
Kjeldahl analyses. 
The resulting spectra of the various proteins which 
were heated with ER as previously described are shown in Chart #4. 
Both pepsin and ovalbumin were insoluble in either the alcohol 
or the acid contained in the ER, or in the 1% monochloroacetic 
acid solution. The last two proteins did show a turbid blue 
coloration. All of the other proteins demonstrated varying 
degrees of clear blue-green-yellow coloration. The 
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.x1-glycoprotein contained a slight shade of pink-red, undoubtedly 
due to its sialic acids content. The relationship of the stable 
blue coloration to the tryptophan contents of the proteins were 
first described by Voisenet (1905) and Rhode (1905). The relation-
ship of absorbancy at 600 mu and the mole ratios of tryptophan in 
proteins are illustrated in Table II. casein has been used in the 
past as a reference standard for the determination of tryptophan in 
proteins by the Ehrlich's reaction. The results obtained with 
crystallized lysozyme in these experiments would suggest that it 
may serve as an excellent reference standard for the determin-
ation of peptide-bound tryptophan in proteins. 
The conditions used in these experiments suggests that the 
number of "buried" tryptophyl groups or residues, are directly 
related to the absorbance at 600 mu wavelength. The unusual 
460 mu absorption behavior of both humen albumin and 
x1-glycoprotein when heated with Ehrlich's reagent could suggest 
tryptophan bound groups or tryptophanyl groups "exposed" in the 
terminal peptide chains of proteins. Human albumin is known to 
bind one mole of tryptophan per mole (~Menamy and Oncley, 1958). 
No information is available concerning "exposed" or tryptophan binding 
to x1-glycoprotein. 
There are no reports concerning the possibility 
that "exposed" or "bound" tryptophyl groups are more sensitive to the 
Ehrlich's reagent than free tryptophan. In view of the sensitivity of 
the "buried" tryptophyl groups to the ER, it would not be unusual to 
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Table II 
THE SPECTRAL CHARACTERISTICS OF VARIOUS PROTEINS TREATED WITH 
"EBBLICH' S REAGENT" AND THEIR RELATIONSHIP TO THE TRYPTOPHAN 
RESIDUES PER MOLE OF PROTEIN 
I Protein Protein Tryptophan* 
Concentration Absorbance Absorbaneeiatio residues/ 
uM X 102 @600 mu x 10l Mole Prote n mole protein 
A Human Albumin 6.2 1.5 0.2 0.63 (a) 
B Bovine Albumin: 4.0 6.5 1.6 2.3 (a) 
c Human Fibrinogen 0.6 16.0 26.6 52.8 (a) 
D cxl-glyeoprotein 4.6 15.5 3.4 3.8 (b) 
(Human) 
E In-insulin 458.0** 2.0 0.0 0.0 (a) 
F Lysozyme 14.5 58.0 4.0 7.7 (e) 
G Chymotrypsin 11.8 38.2 3.2 7.0 (d) 
H Trypsin 13.5 36.2 2.7 X (d) 
* The tryptophan residues/mole of protein were ealeulate4 or obtained from 
following references: (a) Tristram (1953); (b) K.Sehmid, ~ al (1962); 
(e) Anfinsen and Redfield (1956); (d) Desnuelle (1960). 
** No correction was made for Zn content, and calculations are based upon 
air-dry wt. basis. 
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find that the "exposed" tryptophyl groups were somewhat more 
sensitive to ER than free tryptophan. However, tryptophan 
interference in the measurements obtained for the "heat-labile" 
protein hydrazide must be quantitatively small, less than 0.5 
per cent. 
III. The release of carbohydrates and peptide nitrogen during the 
conversion of fibrinogen !£ fibrin 
a) An introductory experiment 
An appropriate introduction which suggested that the 
carbohydrate changes did occur during the conversion of human 
fibrinogen to fibrin was indicated in the following simple 
experiments. 
Paired samples of either oxalated or untreated whole 
blood were collected in approximately equal vo lum.es ( 10 ml.) from 
eleven different hospitalized patients. All the samples were 
allowed to remain at room temperature for approximately one hour, 
and then centrifuged for 20 minutes. The plasma or sera were 
drawn off and again centrifuged for 20 minutes to insure the 
complete removal of erythrocytes. The dialyzable reducing sub-
stances in the samples were measured by the alkaline ferri-
cyanide method as adapted to an Auto-analyzer (Technicon Co.). 
The reducing substances expressed as glucose ranged from 208 to 
72 mgm. per 100 ml. of plasma or serum. The sera values were from 
1 to 4 mgm.% higher than the plasma values, with the average 
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increase of 2.3 mgm.%. The "t" test for small samples was done, 
and a t10 value of 5.5 was found, which indicated that the 
differences were statistically significant at the probability 
level of less than 0.001. Three samples each of oxalated plasma 
were treated with a small crystal of anhydrous calcium chloride, 
and incubated at 37°c. for 1\ hours, along with the untreated 
plasma. The plasma which was allowed to clot was 1 to 2 mgm.% 
higher than the untreated plasma. 
Obviously, blood sugars have been done in the routine 
clinical laboratory for overy forty years, however, the difference 
of 1 or 2 mgm.% in a blood sugar would have little or no clinical 
significance. Furthermore, the measurement of dialyzable reducing 
substances was only recently introduced into the clinical 
laboratories (1957-8), and the paired plasma-sera analyses of 
dialyzable reducing substances has not been hitherto reported. 
b) Method of assay 
The final simple techniques which are presented here 
were developed after many partially successful or otherwise lengthy 
experimental approaches were discarded. Although the reagents 
used in these experiments are common to the biochemist, they 
were altered so much in their concentrations, volumes and 
applications, that a detailed presentation was inevitable. With 
the proper micro-instrumentation the method presented here could 
be applied to measure the peptide nitrogen changes in as little 
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as 2 mgm./ml. of fibrinogen converted into fibrin. 
The purified human fibrinogen (fraction I4) and the human 
thrombin was obtained as previously described. Approximately 11 
grams of the frozen fibrinogen was dissolved at room temperature 
(ca. 23°C.) in 50 ml. of 0.30 M NaCl. The fibrinogen was readily 
soluble within 20 minutes when dissolved with the aid of a 
magnetic mixer. The fibrinogen solution was then diluted to 
100 ml. volume with a phosphate buffer, pH 6.4, ionic strength 
0.1 (this buffer contains 0.003 M Na2HP04; 0.012 M KH2P04, and 
0.075 M NaCl). Triplicate Kjeldahl protein nitrogen analyses 
revealed that the solution contained 32 mgm. of fibrinogen per ml. 
two ml. each of this fibrinogen solution were placed into 25 x 100 
mm. round bottom tubes (except in those experiments relating to 
varying fibrinogen concentrations). A mdxture of 0.3 M NaCl: 
phosphate buffer (1:1) was added to make the final volume equal 
to 4 ml. when the thrombin solution was added. The tubes were 
pre-incubated for 10 minutes at 37°c. before the addition of the 
thrombin solution. 
The volume of the thrombin solution was usually 0.5 ml. 
(2.70 NIH units) except in those cases where the effects of varying 
concentrations of thrombin were studied. The thrombin solutions 
were prepared shortly before each experiment by diluting the 
stock thrombin (270 NIH units per ml.) with the NaCl:phosphate 
buffer mixture. Immediately after the addition of the thrombin a 
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stopwatch and the time clock were started and the clotting times 
were noted. soon after the addition of the thrombin, glass rods 
were placed into each of the incubation tubes. About one minute 
before the designated periods of time which were 10, 30, 60, 90, 
120, 180, and 240 minutes, the glass rods were used to collect 
the clots and these clots were squeezed against the sides of the 
tubes in order to express as much solution from the fibrin clots 
as was physically possible. The removed clots were analyzed for 
fibrin content by the alkaline-urea u.v. absorption method. 
The unclotted fibrinogen and thrombin were precipitated 
by the addition of 1.5 ml. each of 7.5% (w/v) zinc sulfate 
(ZnS04-5H20) solution· and a barium hydroxide solution. The 
barium hydroxide solution was prepared from a saturated 
solution which was diluted until it would exactly neutralize an 
equal volume of the 7.5% zinc sulfate solution at the 
equivalence point of phenolphthaleia. fadieator. 
The thrombin was added to the zero time tube after the 
precipitating reagents. 
A control containing the fibrinogen solution without 
the addition of thrombin was incubated for 240 minutes and then 
treated with the precipitating reagents. 
The mixed precipitates were allowed to remain in beakers 
of cracked ice for 10 minutes and then centrifuged at 
approximately 2500 rpm. for 10 minutes. The clear supernatants 
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were filtered through Whatman #1 filter papers. 
Carbohydrate analyses were conducted by the anthrone-H2so4 
method using 3 ml. of each filtrate. In several cases the results 
were checked by the orcinol-H2so4 method. 
Peptide Nitrogen analysis reagents. The following modifica-
tions of the Lowry biuret-phenol reagents were necessary to obtain 
a final stable blue color: Reagent I contained 40 Gms. of 
anhydrous sodium carbonate and 1.0 Gms. of sodium potassium 
tartrate diluted to 1 liter with distilled water. Reagent II 
contained 0.5% (w/v) copper sulfate (Cuso4-sH20) in distilled 
water. Reagent III- the phenol color reagent was a 1:1 (v/v) 
mixture of the Folin-Ciocalteu reagent and distilled water. 
The peptide nitrogen calibration curve was prepared 
using crystalline human albumin (4 to 16 ugm. N per ml.) 
dissolved in the NaCl:phosphate buffer mixture as the reference 
standards. 
Color Development - To one or two milliliters of the clear 
filtrate (10-30 ug of peptide nitrogen) was added 3.5 ml. of 
reagent I and 0.5 ml. of Reagent II. When 1 ml. of filtrate was 
used, an additional 1 ml. of the phosphate-NaCl buffer mixture 
and water (1:1) was used to bring the volume to 2 milliliters. 
0 The mixture was incubated for 15 minutes at 37 c. and 1 ml. of 
the dilute phenol reagent was rapidly added, mixed, and further 
incubated at 37°C. for 15 minutes. The final blue color reached 
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a maximum intensity in 10 minutes and was stable for at least 
one-half hour. The colorimetric absorbances were made with a 
Coleman Model 14 at 660 mu wavelength using 19 x 150 mm. cuvettes. 
The zero absorbance blank was 1 ml. each of the NaCl-phosphate 
buffer mixture and distilled water which was carried throughout 
the color development procedure. 
Comments - The following types of filtrates could not be 
used with the phenol-biuret method for the peptide nitrogen 
analyses: TCA, phosphotungstic acid, or picric acid. The TCA 
filtrates resulted in a variable and unstable blue color 
development. Phosphotungstic acid precipitated all of the 
peptides, and picric acid could not be used because of its 
phenolic chemical behavior. The colorimetric Stein and Moore 
ninhydrin method was approximately 20 times less sensitive than 
the one described above. 
various other mMolar concentrations of zinc in the 
total volume of 7 ml. were tried. The concentrations of zinc 
between 30 and 60 mM in the volume of 7 ml. did not remove any 
of the human fibrinopeptides by precipitation. As the concentra-
tion of zinc was raised to 70 or 80 mM the second peptide was 
partially removed, but not the first. In the case of the bovine 
fibrinopeptides (A and B) the final concentration of 80 mM zinc 
did not precipitate either peptide. This behavior of the second 
human fibrinopeptide was the first indication that it may be 
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significantly different from that of bovine origin. The use of a 
Znso4-Ba(OH) 2 system for separating the ureacted fibrinogen and 
thrombin from the fibrinopeptides and carbohydrates offers at 
least three advantages: (1) the formed Baso4 provides an 
excellent absorbant for the removal of thrombin; (2) the filtrates 
are clear, consistent, and reproducible; (3) any protein 
contamination in the commercial heparin preparations are like-
wise removed. 
c) Effects of increasing thrombin concentrations: Using 
the described assay system, the release of the peptides and 
carbohydrates were made with increasing amounts of human 
thrombin (0.005 to 2.0 NIH units/ml.) in the total volume of 
4 ml. The fibrinogen concentration was constant at 16 mgm./ml. 
and the incubation time was 30 minutes in all cases studied. 
The results are shown in Fig. 4. Under these conditions a 
maximum release of peptide nitrogen and hexoses was obtained 
at O.Ol NIH units/ml. of human thrombin. 
d) Effects of increasing fibrinogen concentrations: The 
thrombin concentration was constant at 0.34 NIH units/ml. and 
the fibrinogen concentration was varied between 8 and 32 mgm./ml. 
in a total volume of 4 ml. A slight decrease of the released 
peptide nitrogen was noted when the fibrinogen concentration 
increased. A similar decrease in the per cent clottability 
(43 to 36%) was also found. The results are shown in Fig. 5. 
() 
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e) I!'llt release of peptides !!!! carbohydrates !t!!!:!. respect 
S2, ~: The per cent of fibrinogen transformed into 
fibrin clot, the release of peptides and carbohydrates at various 
periods of time are presented in Fig. 6. The clotting time was 
9% Ddnutes as described by the first visual appearance of a 
fibrin clot. There was a direct relationship between the per 
cent of clot recovered and the first release of peptide nitrogen 
(designated as A). The second peptide (B) released was not related 
to the per cent of clot recovered. The second peptide released 
suggest that either another proteolytic enzyme system was auto-
activated during the conversion of fibrinogen to fibrin or that a 
second ~oteolytic enzyme was present in the system which was 
specific for fibrin rather than fibrinogen. The fibrinogen control 
which was incubated to 240 minutes in the absence of thrombin was 
found to liberate 10 ug. of peptide nitrogen. 
As mentioned previously, the fibrinogen used in these experiments 
may contain• about ten per cent of the plasminogen which was present 
in the starting Cohn fraction I. This plasminogen can be auto-
catalytically converted into the active proteinase, plasmin, 
which will digest fibrin much more readily than fibrinogen. The 
second proteolytic type of enzyme which is present in the fibrinogen 
used in these experiments has been called 'fibrin-stabilizing factor', 
'fibrinase' or L-L factor (Lorand, !!!l, 1959). The presence of fibrin-
~ ~ 6"0. ~ ~ 
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~ ~30 ~ 
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human thrombin. Total volume • 4 al. Ti• 0 ·to 240 ainutea 
t• clotting tt.a (9\ ainutea). 
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" stabilizing factor in the fraction 14 was not reported by Blomback, 
however, in some later experiments it was found that at least 9~ 
of the fibrin which was formed with the fraction 14 was not soluble 
in either 1 Molar sodium bromide or 6 Molar urea. A recent communi-
cation with Dr. Mosesson has confirmed the author's impression that 
plasminogen-free fibrinogen preparations would also contain variable 
amounts of fibrin-stabilizing factor. 
f) Effect of S-amino-caproic ~ ~ sodium heparinate ~ 
the activities £t thrombin. 
As mentioned previously the fibrinogen used in these 
experiments was said to contain approximately ten per cent of the 
plasminogen which was present in the starting Cohn fraction I. 
This plasminogen can be auto-catalytically converted into the 
active proteinase, plasmin, which will digest fibrin much more 
readily than fibrinogen. The presence of 10·4 M e-amino-caproic 
acid bas been shown to inhibit the conversion of plasminogen to 
plasmin, however, concentrations of lo-2 Molar were found necessary 
to inhibit 90 per cent of the plasmin activity (Alkjaersig, 1959). 
The incorporation of lo-3 M e-amino-caproic acid (EAC) 
into the assay system did not decrease the amounts of peptide 
nitrogen released at 40 minutes and the total peptide nitrogen 
released at the end of 240 minutes was only reduced from 178 to 
170 ugms., indicating that fibrinopeptide B does not arise from 
the action of plasmin on fibrin. An exhaustive study which may 
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implicate plasmin in the release of human fibrinopeptide B was 
not done. A detailed study of this type requires that 
plasminogen-free fibrinogen or higher concentrations of EAC be 
employed in the assay system. 
Since E-amino-caproic acid is currently being used in 
clinical trials to inhibit the action of plasmin in fibrinolytic 
diseases, it was interesting to find out if the presence of 
E-amino-caproic acid would inhibit thrombin as well as plasmin 
and therefore effect the one stage prothrombin time. The 
Simplastin preparation (Warner-Chilcott Co.) is commonly used 
for clinical prothrombin determinations and this preparation was 
made to contain various concentrations of f-amino-caproic acid 
-3 -1 1 from 10 to 10 • A Simplastin preparation containing 10· M 
glycine was taken as an appropriate comparative control. The 
prothrombin times are given as the average of two separate 
determinations and the differences of the duplicate determinations 
was less than 0.3 second. The following Table III illustrates 
the effects of glycine and £-amino-caproic acid on a normal 
prothrombin time of 13.0 seconds. 
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TABLE III 
Effects of €-amino caproic acid~ the one-stage prothrombin times. 
Concentration 
e - amino caproic acid 
e - amino caproic acid 
e - amino caproic acid 
lo-3 
10-1 
10-l 
Prothrombin Time 
(seconds) 
14.4 
14.4 
14.4 
glycine (control) 10-1 13.5 
Eleven citrated plasma specimens were randomly taken from 
the hospital morning samples and prothrombin determinations were 
-1 
made in the presence of 10 Molar ~-amino caproic acid. The values 
given in ( ) were obtained in the absence of €-amino caproic acid. 
The following prothrombin times were obtained: 20.7 (18.0); 13.2 
(12.3); 19.0 (18.6); 27.4 (24.2); 25.9 (23.3); 13.6 (12.8); 11.0 
(10.6); 21.7 (20.7); 14.4 (13.0); 34.3 (31.0); 19.9 (18.0). 
It may be concluded that l-amino caproic acid does not 
have any marked effects on either the conversion of prothrombin to 
thrombin by the action of thromboplastin, or the conversion of 
fibrinogen to fibrin by the action of thrombin. 
The previously described assay system, Experimental 
Section III, part b, was used to study the effects of heparin on 
the release of peptides from fibrinogen. The stock sodium heparin 
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solution 10,000 USP Units/ml. (ca. 100 mgm.) Testagar & co., Lot 
#12726 was diluted with the pH 6.4, phosphate-NaCl buffer mixture 
to the concentrations of 100, 300 and 500 USP Units/0.5 ml. The 
clotting times were prolonged from 9'30" to 12'4", 17'0" and 
24'15" respectively when the above concentrations of heparin were 
present in the assay system. However, none of these concentrations 
of heparinate added to the above assay system would prevent the 
eventual formation of a fibrin clot. The fibrin clots could not 
be completely collected on the glass rods within the stipulated one 
minute interval allotted for their collection. As much of the clot 
as possible was removed and the remaining small discrete clots were 
left to be removed during the precipitation and filtration procedure. 
None of the above concentrations of heparin showed any pronounced 
effect on the amounts of peptide nitrogen released after a 40 minute 
incubation period. The amounts of peptide nitrogen found at the 
end of the 40 minutes wa~e55, 58, and 50 ugms. for the above 
concentrations of heparin as compared with 53 ugms. when heparin was 
not present. The addition of 300 USP units of sodium heparinate 
to the assay system at 0, 3 and 6 minutes did not affect the amounts 
of peptide nitrogen found at the end of the 40 minute incubation 
period, which was 53, 57, 56 ugms. In later experiments concerning 
the effects of heparin on fibrin polymerization, it was found that 
the clots could have been collected and completely recovered by 
snaring on a stiff nichrome loop. 
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Therefore heparin ~eta»ds clot formation in these ex-
pertments without affecting the release of either fibrino-
peptides A or B. 
IV. Some kinetic considerations concerning the polymerization of 
human fibrin in the presence of heparin 
a) Introductory remarks 
There are many observations concerning the clotting rates 
of fibrinogen transformed into fibrin, but the complete kinetic 
study regarding the thrombolytic conversion of fibrinogen into 
fibrin monomers and thence into fibrin polymers has not been done. 
The nature of the polymerization of fibrin has been a subject of 
lively discussion during the past twenty years, since Laki and 
Mommaerts (1945) demonstrated that at low pH values that thrombin 
changed fibrinogen in some way that the coagulation time was 
shortened after reneutralization. Steiner and Laki (1951) 
demonstrated by light scattering measurements that fibrin 
polymerization occurs in two ways, i.e., end-to-end aggregation 
and lateral aggregation.- Ferry, et al (1952) using similar 
measurements in the presence of 1M urea at pH 6.3, showed that 
the fibrin polymer under these conditions consisted of 15 monomers 
with a thickness of a double monomer, and thue Ferry introduced the 
term 'side-by-side' aggregation.-·-· Waugh and Livingston (1951) 
were among the first to study the kinetic behavior of what can now 
be called the "thrombin-fibrinogen-fibrin" system and found that 
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the formation of fibrin was a pseudo first order reaction. 
II Blomback and Laurent (1957) were probably the first to recognize 
that the fibrinopeptides released from fibrinogen and the poly-
merization of fibrin were separate kinetic reactions. and had they 
known that the latent release of the second fibrinopeptide (B) 
was not a requirement for coagulation to occur as shown by 
Shainoff (1963); then their molecular weight-~light-scattering 
studies would probably have been done on the conversion of fibrin 
monomers to polymers. However, they were able to indicate 4C"'"' ·pH 
6.4 and 7.4 that the increase in molecular weight was initially an 
end-to-end polymerization; whereas, at higher pH values (9.0 and 9.9) 
the lateral aggregation of fibrin also initially occurred. Therefore, 
all of the kinetic reaction studies done at pH values near 6, whether 
the measurements were by light scattering, calorimetic, or uv280 mu 
absorption, have indicated that the polymerization of fibrin is apparently 
a first-order reaction (Sturtevant~!!, 1955). 
Since the presence of heparin did not appear to retard 
the release of peptide nitrogen in the experiments (Section III, 
g), but did delay the appearance of the fibrin clots, it was 
necessary to make some observations regarding the "monomeric-
polymeric" fibrin system. The experimental approach was in many 
ways= similar to the classical experiment of Waugh and 
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Livingston (1951), who used only the "thrombin-fibrinogen-fibrin" 
system. In designing the experiment presented in this section, 
the assumption was made that if equal amounts of monomeric fibrin 
solutions were made to contain either no heparin or different 
concentrations of heparin, then any changes in the fibrin poly-
merization rates would be due to the presence of heparin. Al-
though such variables as actual heparin concentration, volume, 
ionic strength, and osmotic pressure changes were not made, the 
data obtained from the measurements of bromide concentrations, 
fibrin monomers (soluble fibrin), fibrin polymer (fibrin clots) 
and time were encouraging and are presented as a qualitative 
index regarding the effects of heparin on the polymerization of 
fibrin. 
b) The experimental conditions used to measure the 
polymerization of fibrin monomers in the presence and 
absence of heparin. 
Approximately 2 gms. of fibrin were washed with 
distilled water and then dissolved in 200 ml. of solution con-
taining 1.0 ~ NaBr;0.003 ~ Na2HP04;0.012 ~ KH2P04 and 0.075 ~ 
NaCl per liter. The dissolved fibrin was filtered through cotton 
gauze, and 25 ml. each was placed in three 50 ml. volumetric 
flasks, #1 containing 1 ml. of the phosphate-NaCl buffer and 
12 and #3 containing 1 ml. each of sodium heparinate (50 or 
100 mgm.) in the phosphate-NaCl buffer mixture. All of the 
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flasks were diluted to volume and mixed with the 1.0 M NaBr-
phosphate-NaCl mixture. Each fibrin monomeric solution was placed 
in separate Visking dialysis bags (32/23) which were wired with 
open glass tube flanges to permit access to the dialysis bag. All 
three dialysis bags were placed into a liter cylinder containing 
950 ml. of the phosphate-NaCl buffer mixture, pH 6.3, so that the 
contents of each bag was submerged below the liquid level of the 
cylinder. The contents of the cylinder was continuously mixed 
and exchanged with the buffer mixture at the rate of 1 liter/65 
minutes at 21°C. An aliquot (5 ml.) was removed from each 
dialysis bag at various timed intervals (0,27,37,47,57, and 67 
minutes). If any fibrin clots (fibrin polymers) were formed they 
were removed prior to the 5 ml. aliquot& (fibrin monomers). The 
fibrin clots and monomeric fibrin solutions were both analyzed for 
280 mu fibrin contents by the alkaline-urea method at UV • The 
monomeric fibrin solutions were also analyzed for bromides by 
the gold chloride method. A graphic representation (Figure 7) 
indicates that the critical sodium bromide concentration for 
fibrin polymer formation was 0.41 Molar NaBr. A range of 
0.34-0.45 Molar sodium bromide was reported by Shulman (1953) 
as the minimum inhibiting concentration for the clotting of 
fibrinogen by thrombin at pH 6.2, ionic strength 0.45. The 
range suggested by these experiments appears considerably narrower, 
and is not markedly changed by the presence of sodium heparinate. 
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The amounts of protein present in each clot (expressed 
as mgm. of fibrin polymer) at the various timed periods are 
represented in table IV., along with the parentheticaL:-· expressions 
of the fibrin polymer-monomer ratios. Upon initial inspection of 
the amounts of fibrin clots formed in the presence of heparin, 
it would appear that heparin had delayed the formation of the 
fibrin polymer. However, when the logarithmic function of the 
fibrin polymer/monomer ratios we~plotted against the linear 
time measurements (Figure 8), it is noted that the polymerization 
of fibrin proceeds at apparently a first-order kinetic rate, 
and that the presence of heparinate does not merely depress the 
initial rate but would appear to alter the kinetics of fibrin 
polymerization. Since the physico-chemical characteristics of 
the heparin used in these studies can only be assumed, the 
absolute evaluation of the kinetic results does not seem 
permissible. 
The kinetic data would tend to support the view expressed 
by Seegers (1955), which is that heparin interferes with the 
polymerization reactions. Furthermore, the total amounts of 
fibrin polymer obtained in samples 2 and 3 at 67 minutes and the 
accelerated reaction rates at this time would support the view 
expressed by Shinowara and Everhart (1949), which is that heparin 
does not inhibit the clotting of pure fibrinogen preparations.· 
In other words, heparin initially depresses the rate of fibrin 
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TABLE IV 
Total amounts of fibrin polymers (clots) obtained during the ~ 
merization of fibrin monomers. 
Time Sample #1 Sample #2 Sample #3 
~minutes} ~no he2arin} ~50 mgm. he2arin} ~100 mgm. he2arin} 
27 5.5 (0.026) 4.4 (0.021) 0.6 (0.003) 
37 13.5 (0.078) 10.9 (0.050) 5.8 (0.028) 
47 29.3 (0.17) 14.2 (0.07) 16.6 (0.083) 
57 39.9 (0.29) 27.1 (0.16) 31.8 (0 .17) 
67 40.9 (0.41) 45.6 (0.37) 46.6 (0.35) 
The milligrams of fibrin polymers (clots) and remaining fibrin 
280mu 
monomers were obtained by alkaline-urea uv1 em. measurements of 
the samples obtained at various periods of time (minutes) during the 
polymerization reaction. The parenthetical expressions are the 
ratio of polymer to monomer at these various times. 
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polymerization, however the final amounts of polymer formed are 
the same in the presence ot absence of heparin. 
V. The effects of heparin~ various proteolytic eneymes derived 
fi:2!! human plasma 
a) Introductory remarks 
The previous experiments indicated that the effects of hepa.rin 
were on the polymerization of fibrin monomers, ra.ther than on the 
proteolytic activity of the human thrombin preparation used in these 
experiments. Another experimental approach was undertaken to show that 
the effects of heparin were not on the enzymatic activity of thrombin. 
The synthetic substrate chosen was benzoyl-1-arginine ethyl ester 
(BAEE), which was shown by Sherry and Troll (1954) to be hydrolyzed 
by both plasDdn and thrombin. The synthetic arginyl substrates such 
as BAEE are not specific for any particular enzyme, however, these 
substrates are frequently used to indicate the presence of enzymes 
of the trypsin-like group. Because of the immediate quantitative 
data obtained with arginyl substrates, they are used to follow 
the purifica.tion steps of trypsin-like enzymes. In the case of 
plasDdn, Ronwin (1961) has shown that the esterase activity of 
various plasudn preparations on BAEE does not parallel their 
proteolytic activity, and has suggested the existence of more 
than one plasudn. 
Several years ago the author, Brown (1960), found that 
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the addition of heparin to normal human sera, oxalated or citrated 
plasma would increase their arginyl esterase activities.·· 
Forde, et al (1962) utilizing this method were able to report 
that heparin increased the arginyl esterase activity of oxalated 
plasma. · However, they did not describe any plasma protein 
fraction as being involved in the "activation effect" of heparin 
on the hydrolysis of BAEE by human plasma. 
The following observations and kinetic data are 
presented with the realizations, first, that commercial heparin 
preparations were used, and therefore may not strictly apply to 
studies conducted with purified human heparin; secondly, that a 
heparin activated plasma protein fraction which hydrolyzes BAEE 
and is free of plasminogen, plasmin, and thrombin has not yet 
been prepared. The author has found that the "activation effect" 
of heparin can be demonstrated with the commercial thrombin-
enriched, plasmin-poor fraction of plasma proteins which represents 
less than two per cent of the total plasma proteins. 
b) The relationship of heparin concentrations ~ the 
hydrolysis of BAEE and acetylcholine ~ plasma and !!!! 
The details of these experiments were as follows: 
The pooled oxalated human plasma and serum samples were 
obtained from five hospital blood donors. The word "pooled" 
designates that these samples were used in the experiments. 
Other experiments were conducted on randomly collected serum 
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1 
samples and received no special designation. 
The alkaline hydroxamate-ferric chloride colorimetric 
method of Brown (1960) was used to determine the UMoles of BAEE 
or acetylcholine hydrolyzed per milliliter of plasma or serum per 
hour. The assay system was made to contain between 4 and 
100 ugms. of sodium heparinate (Testagar & c., Lot 112726) per ml. 
in a total volume of 2.5 ml. The relationship of heparin 
concentrations to BAEE hydrolysis by the pooled plasma and sera 
are shown in Figure VI. Heparin concentrations greater than 
40 ugms. and up to 100 ugms. per ml. resulted in approximately 
a two-fold increase of the sera or plasma arginyl esterase 
activities. The activation effect of heparin on the sera arginyl 
esterase activity appears to be slightly greater than on the 
corresponding plasma sample. Incubated substrate controls 
containing similar heparin concentrations without plasma or sera 
did not demonstrate any arginyl esterase activity. Furthermore, 
four heparin preparations obtained from different manufacturers 
were all found to increase the serum arginyl esterase activity 
in an equivalent manner. These heparin preparations contained 
either chlorobutanol, phenol, or benzyl alcohol as an added 
preservative. The addition of 100 ugms. of phenol instead of 
heparin did not result in an increase of the serum arginyl 
esterase activity. These results were taken to mean that the 
"activation effects" of heparin were not restricted to any one 
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particular heparin preparation, and were not due to the 
preservative added. 
The acetylcholine hydrolysis by serum was 162 uMoles 
per ml. per hour and was not significantly changed by heparin 
concentrations up to 200 ugms. per ml. These results would 
suggest that the effects of heparin were limited in its serum 
esterase activation. The BaS04 or ca3(P04) 2 treatment of plasma 
or serum is said to remove both thrombin and prothrombin. 
several serum samples (9) were separately mixed with 150 mgm.of 
Baso4 per ml. of serum and allowed to stand for 10 minutes. 
The BaS04 was removed by centrifugation. There was found a 
variable decrease of the Baso4-treated serum arginyl esterase 
activities which averaged 6 uMoles per ml. per hour. 
The pooled sera were treated with 200 mgm. of 
ca3(Po4) 2 per ml. of sample and allowed to stand for 10 minutes 
before centrifugal removal of the ca3(Po4) 2• The ca3(Po4>2-
treated-sera was found to decrease the arginyl esterase activity 
from 25.5 to 14.8 uMoles per ml. per hour. The effects of 
heparin (10, 20, 40, 60 and 100 ugms.) on the arginyl esterase 
activity of the ca3(Po4) 2-treated-sera were studied and the 
results are shown in Figure VI. The optimum concentration of 
heparin for the maximal increase of arginyl esterase activity 
was found to change from 40 ugms. per ml. to approximately 
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10 ugms. per ml. following ca3(P04) 2 treatment, however, the two-
fold increase of activity due to the addition of heparin remained. 
These results were suggestive that human thrombin was not involved 
in the heparin "activation effect" on the serum arginyl esterase 
activity. 
c) The effects of heparin ~ the enzymatic activities of 
crude and column purified human thrombin 
various amounts of crude human thrombin or column 
(Cellex-P) purified human thrombin (courtesy of Dr. J. Inman, 
Ortho Research Laboratories) were assayed for arginyl esterase 
activities. The purified human thrombin was said to be free of 
plasminogen and plasmin. The addition of 1,000 to 5,000 Units of 
streptokinase (Varidase) failed to increase the arginyl esterase 
activities of either the crude or purified human thrombin 
preparations. A$ shown in Figure VII, the uMoles of BAEE hydrolyzed 
per hour were related to the NIH clotting Units in both 
preparations. The purified thrombin preparation was slightly more 
active than the crude thrombin, in terms of their arginyl ester 
hydrolysis per NIH Units of thrombin. 
The relationship of various heparin concentrations to 
the esterase activities of these two thrombin preparations were 
remarkably different as shown in Figure VIII. Various amounts 
of heparin did not demonstrate an "activation effect" on the 
purified thrombin enzymatic activity, whereas, the effect of 
It# 
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heparin on the enzymatic activity of the crude thrombin prepara-
tion was iimilar to that observed with human plasma or serum. 
These results in conjunction with those obtained with 
plasma and serum would support a suggestion that a heparin 
dependent enzyme (capable of hydrolyzing BAEE) is present in the 
plasma, serum, and crude thrombin preparations, and that this 
enzyme is not thrombin, per !!.· 
Similar observations regarding the "activation effects" 
of heparin on commercial bovine thrombin preparations (Upjohn Co. 
and Parke-Davis Co.) have also been made by the author. " Blomback 
II 
and Blomback (1958) have shown that the esterase activity of 
purified bovine thrombin, as measured on tosylarginine methyl 
ester, was not inhibited by heparin alon~, however, they did not 
indicate the effects of heparin on the crude bovine thrombin 
preparation. 
The author has been unable to demonstra•e the heparin 
"activation effect" with either commercial plasminogen or plasmin 
preparations, and has not been able to activate plasminogen with 
purified thrombin in either the presence or absence of heparin. 
A competitive inhibition between plasmin and purified thrombin 
for the BAEE substrate can be demonstrated, and a similar type of 
inhibition has been reported by Pechet and Alexander (1962) using 
fibrinogen as the substrate. Heparin additions ha4 no effect 
on the competitive inhibition between plasmin and thrombin for 
the substrate BAEE. 
DISCUSSION AND SUMMARY 
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The criterion of the clottability of fibrinogen is an 
additional parameter of protein purity which is not shared by other 
plasma proteins. This unique clotting characteristic of the fibrinogen 
molecule can be readily altered by enzymatic and cheudcal treatment. 
Mihalyi (1963) has shown that the controlled tryptic cleavage of a 
single peptide bond will render the molecule non-clottable. The 
acetylation of 35 per cent of the free audno groups (Caspary, 1956), 
or the guanidination of 75 per cent of the lysyl groups (Kominz and 
Laki,l954), or the iodination of the tyrosyl groups (Laki and Steiner, 
1952) of fibrinogen were found to produce a non-clottable molecule. 
Laki and Mester (1962) reported that the treatment of fibrinogen with 
periodic acid for various periods of time would result in a gradual 
decrease in the clottability, and the sialic and carbohydrate contents 
of the molecule. The experiments presented in this dissertation indicated 
that the controlled hydrazine treatment of fibrinogen would result in 
the formation of a fibrinogen-hydrazide Which was non-clottable. The 
ultracentrifuge comparative study of the treated and untreated fibrinogen 
suggested that the major portion of the molecule remained intact. The 
spectrometric evidence has indicated that the fibrinogen-hydrazide contains 
three moles of heat-labile hydrazine per mole of fibrinogen. 
The definitive reports of the Gallop group concerning the 
conditions for the hydrazine reaction with ester-like linkages 
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were followed in these experiments on the human plasma proteins 
and fibrinogen was found to be the only plasma protein to 
demonstrate any extensive reaction with hydrazine. This would 
suggest that ester-like linkages are present in fibrinogen. 
Bergmann, et al. (1939) suggested but were unable to exclude the 
possibility of ester or ester-type linkages in the fibrinogen 
molecule. The failure of o{1-glycoprotein to react with 
more than 0.32 moles of hydrazine per mole of protein would 
exclude the possibility that the hydroxyl groups of the carbo-
hydrates had reacted with hydrazine under the conditions used 
in these experiments. And it would tentatively exclude the 
possibility that the carbohydrate peptide linkage of 
eel-glycoprotein was of an ester-type. Due to the larger 
amounts of hexoses in ~-glycoprotein (16%) as compared with 
fibrinogen (1.6%), it would seem reasonable to suppose that 
the carbohydrate-peptide bonds of the former protein were not 
readily accessible to react with hydrazine, whereas the 
carbohydrate peptide bonds of the latter protein were 
accessible. It will be of some interest to test this possi-
bility either, by a longer treatment of o(1-glycoprotein, or 
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the controlled hydrazine treatment of ovalbumin (1.8% hexoses). 
The finding of only 0.2 moles of heat-labile hydrazine per mole of 
hydrazine-treated human albumin would suggest that the ester-like 
linkages are not found in the molecular structure of this protein. 
The lack of ester-like linkages in albumin would suggest that those 
found in fibrinogen were not due to its secondary or tertiary 
structure. The probable existence of one ester-bond per mole of 
bovine albumin has been suggested by Gallop (1962a), but no 
further reports have appeared to validate this communication. 
The carbohydrates of fibrinogen are not genera~ly recognized, 
however, the chromatographic demonstration of mannose, galactose, 
hexosamine, and sialic acid in these experiments has firmly 
established fibrinogen as a glycoprotein. The percentages of 
hexoses, hexosamines, and sialic acids found in the fibrinogen 
preparation used in these experiments differ from those reported 
.. 
by Blomback for bovine fibrinogen (see page 15). The hexose and 
hexosamine values a.re in agreement with those reported by Bagdy and 
those currently being obtained by the NIH group (Laki and Mester, 
1962). The sialic acid content disagrees with the value of "none" 
reported by Bagdy and somewhat with the value of 0.6% currently 
being found by the NIH group. The difference in the amounts of 
sialic acids is probably due to the difference in the methods used 
to determine sialic acids. Based on the values of the various 
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carbohydrate components it was calculated that human fibrinogen 
(M.W.=340,000) would contain approximately 29 residues of neutral 
hexoses (M.W. galactose=l80); 9 residues of N-acetyl hexosamines 
(M.W.=221); and 10 residues of sialic acid as N-acetyl neurandnic 
acid (M.W.•309). During the molecular conversion of fibrinogen to 
fibrin there would be released approximately 5 residues of hexoses, 
probably as galactose moieties and 1 residue of N-acetyl neuraminic 
acid. 
The finding of differences in the dialyzable reducing substances 
of the paired serum and plasma analyses and the indication that 
hexoses are released during the ooaversion of fibrinogen to fibrin 
would support the hypothesis that hexose-release was involved in 
the blood coagulation meChanism. Some of the differences between 
the paired serum-plasma analyses are probablJ due to the conversion 
of prothrombin to thrombin. Miller and Seegers (1956) reported 
that dunog the conversion of prothrombin to thrombin, there was 
released 40 to 60 per cent of the hexoses of prothrombin (presumably 
as tetrasaccharide& consisting of glucose moieties. 
The release of peptides during the conversion of fibrinogen to 
fibrin has already been established. However, the clear indication 
that human fibrinopeptide B release occurs after the formation of 
fibrin bas only recently been reported (Brown, 1962). 
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The release of fibrinopeptide B did not appear to involve 
proteolytic activities of plasmin in these experiments. The recent 
reports of Lorand, !! al (1962) indicated that the role of the 
fibrin~stablizing-factor (FSF) was one of transpeptidation; it would 
be interesting to speculate that fibTinopeptide B release was 
associated with FSF. Some preliminary experiments concerning the 
electrophoretic comparisons of human and bovine fibrinopeptides 
indicated that both of the human fibrinopeptides A and B were 
different from those serived from bov.ine fibrinogen. A review of 
II II 
the reports by Blomback and Sjoquist (1960), Shainoff and Page (1960) 
and Doolittle_!! al (1962) clearly indicated the marked electro-
phoretic differences of bovine, rabbit, lamprey eel, sheep, and 
dog fibrinopeptides. Our Sakaguchi-reaction for arginine has not 
been stabiized enough to permit photographic reproductions. However, 
under the paper electrophoretic conditions which were similar to 
those used by the above authors, we found that both of the human 
fibrinopeptides migrated toward the positive pole. The mobilities 
of the human fibrinopeptides A were similar to those reported for 
eel fibrinopeptides A, and that the migration of human fibrinopeptides 
B were similar to those reported for dog fibrinopeptides B. The 
human fibrinopeptides B yielded about a two-fold stronger Sakaguchi 
positive area than the positive area of fibrinopeptides A. 
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The role of heparin on the fibrinogen, fibrin monomer, and 
thrombins used in these experiments suggests that: (a) heparin 
does not affect the proteolytic or esterase activities of purified 
thrombin; (b) fibrin monomers are probably formed in the presence 
of heparin; (c) at the milligram ratio of 1:2 (heparin:fibrin monomer) 
an interaction occurs between heparin and fibrin monomer which delays 
the polymerization of the fibrin monomers; (d) microgram quantities 
of heparin have an "activation" effect on the arginyl esterase of 
crude but~ purified human thrombin preparations. It is tempting 
to associate the two types of aggregation of fibrin monomers with 
the possible effects of heparin, that is, the end-to-end association 
occurring primarily in the absence of heparin and the secondary 
side-by-side association occurring in the presence of heparin. 
In conclusion, a number of the planned studies concerning the 
release of carbohydrates and peptides during the conversion of 
fibrinogen to fibrin were reduced, because of the limited supply 
of column purified thrombin which was available. The necessity of 
using proteins which are highly purified is obvious, especially 
concerning studies of such a complex biochemical mechanism as 
blood coagulation. 
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SUMMARY:: 
1) Both human and bovine fibrinogens react with buffered 
hydrazine to form a non-clottable fibrinogen-hydrazide. The spectro-
metric analyses indicated that three moles of "heat-labile" hydrazine 
per mole of human fibrinogen were formed during the reaction. Human 
albumin and ac1-glycoprotein were also found to react with buffered 
hydrazine to form less than 0.5 mole of "heat-labile" hydrazine 
per mole of protein. The results suggest that there are ester-like 
bonds in the primary structure of fibrinogen. 
2) The "Ehrlich's reaction" used with the above proteins and 
others (insulin, lysozyme, trypsin, chymotrypsin, and bovine albumin) 
indicated a spectral characteristic absorption curve at wavelengths 
between 630 and 580 millimicrons which ::are associated with the number 
of tryptophyl residues per mole of the respective protein. 
3) The carbohydrate components of human fibrinogen (fraction r4) 
II II 
prepared according to Blomback and Bl~ack (1956) were determined 
as: 1.6% hexoses; 0.61 hexosamines; and 1.0% sialic acids. The 
calculated carbohydrate residues per mole of fibrinogen (M.W. 340,000) 
are approximately: 29 residues of hexoses; 9 residues of hexosamines; 
and 10 residues of sialic acids. The fibrin monomer contains 
approximately 5 and 1 residue(s) less of hexoses and sialic acid, 
respectively. The hexoses were identified from fibrinogen and 
fibrin digests as mannose and galactose (approximately equal amounts 
of each). The type of sialic acid in fibrinogen was similar to that 
I 
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obtained from the human cx1-glycoprotein preparation. 
4) An assay system was described which indicated that the 
release of carbohydrates and peptide nitrogen occurred during the 
conversion of human fibrinogen to fibrin. The latent release of 
the human peptide nitrogen component B suggested that fibrinopeptide 
B was not associated with the formation of fibrin polymer (clot). 
The rate of peptide nitrogen A release was associated with the form-
ation of the fibrin polymer (clot). The peptide nitrogen A release 
was not altered by various amounts of heparin added to the assay 
system. 
5) The addition of heparin to fibrin monomers dissolved in 1 
Molar sodium bromide and then dialyzing-out the sodium bromide under 
controlled conditions permitted a study of fibrin polymerization. 
The studies indicated that the presence of heparin had a profound 
effect on the apparent first-order kinetics of fibrin polymerization 
which were observed in the absence of heparin. A critical sodium 
bromide concentration for fibrin polymerization was found at 0.41 
Molar sodium bromide. 
6) The addition of heparin in microgram amounts to the arginyl 
esterase measurements of purified thrombin activities had no effects 
on the esterase activity of this thrombin preparation. However, an 
"activation effect" of heparin on the arginyl esterase activities 
of serum, plasma, calcium phosphate-treated serum and crude thrombin 
preparations was observed. 
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ABSTRACT 
THE RELATIONSHIP OF CARBOHYDRATES AND PEPTIDES IN HUMAN 
. FIBRINOGEN AND FIBRIN 
Three purified human plasma proteins, albumin, CK1-glycoprotein 
(prepared according to Schmid) and 96 per cent clottable fibrinogen 
" (prepared according to Blomback, fraction I4) were found to react 
with 1 M hydrazine at pH 9.0 under conditions similar to those used 
by Gallop, et al. for determining the ester-like bonds in collagen. 
The moles of "heat-labile" hydrazine per mole of each human plasma 
protein studied were approximately: 0.2 for albumin, 0.3 for 
CK1-glycoprotein, and 3.4 for fibrinogen. The spectral absorption 
curves of the "heat-labile" hydrazine derived from the treated 
proteins were comparable with those obtained for the hydrazine 
standards. The kinetics of reaction time and the pH optimum for 
the formation of fibrinogen-hydrazide were studied. The small 
amounts of hydrazine reacted with CK1-glycoprotein would suggest 
that the hydroxyl groups of the carbohydrate moiety of glyco-
proteins are not involved in the hydrazine reaction used in these 
experiments. The amounts of hydrazine reacted with albumin would 
suggest that the hydrazine reaction with the plasma proteins used 
in this investigation is unique for fibrinogen. 
Some preliminary physico-chemical characteristics of the 
fibrinogen-hydrazide preparations were: a) the complete loss of 
clottability as compared with only 12 per cent loss in the clot-
tability of the control treated fibrinogen preparation, b) paper 
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electrophoretic mobility of fibrinogen-hydrazide was similar to 
that of the original fibrinogen preparation, c) a single compara-
tive ultracentrifuge run indicated the homogeneity of the original 
fibrinogen preparation suggesting a peculiar aggregation of the 
fibrinogen-hydrazine preparation which apparently sediments similar 
to the original fibrinogen preparation. 
The "Ehrlich's reaction" used in these experiments was applied 
to several carbohydrates, amino acids, and other proteins (insulin, 
lysozyme, chymotrypsin, trypsin, and bovine albumin), and resulted 
in characteristic spectral absorption at wavelengths between 630 
and 580 millimicrons related to the number of tryptophanyl resi-
dues per mole of the respective protein. 
The analyses of carbohydrate components of human fibrinogen 
preparations indicated approximately: 29 residues of hexoses 
(chromatographically identified as approximately equal amounts of 
mannose and galactose); 9 residues of hexosamines; and 10 residues 
of sialic acids (chromatographically similar to those obtained from 
~1-glycoprotein). Fibrin contains approximately 5 to 6 and 1 to 2 
residue(s) less of hexoses and sialic acids, respectively. It is 
suggested that human fibrinogen be considered as a plasma glyco-
protein. 
An assay system is described which indicates that carbohydrates 
and peptide nitrogen are released during the conversion of human 
fibrinogen to fibrin. The latent release of peptide nitrogen B 
suggests that fibrinopeptide B is ~ associated with the formation 
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of fibrin polymer (clot). However, the rate of peptide nitrogen 
A could be related to the per cent of clot formed. The carbo-
hydrate release appears to be concomitant with the release of 
peptide nitrogen A. 
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The incorporation of 10 M of e-amino caproic acid (an 
inhibitor of plasmin activity) into the assay system did not 
significantly affect the release of either peptide nitrogen A or 
B. The negative effects of e-amino caproic on clinical pro-
thrombin times were consistent with these results. The addition 
of 50 to 100 milligrams of heparin (sodium salt) at various times 
into the assay system delayed the clotting times but did not 
effect the release of peptide nitrogen A. 
The addition of 50 or 100 milligrams of heparin to fibrin 
monomers (213 mgm.) dissolved in 1 M sodium bromide permitted 
the preliminary study of fibrin polymerization, and the critical 
sodium bromide concentration for fibrin polymerization was found 
at 0.41 Molar sodium bromide. The studies indicated that the 
presence of heparin had a profound retarding effect on the ap-
parent first-order kinetics of fibrin polymerization which was 
observed in the absence of heparin. 
The addition of heparin in microgram amounts to the arginyl 
esterase measurements of column purified thrombin activities had 
~ effect on the esterase activity of this thrombin preparation. 
However an "activation effect" of heparin resulting in an increase 
of the arginyl esterase activities of serum, plasma, calcium phos-
phate-treated serum and crude thrombin preparations were observed. 
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